Delaware |
3714 |
83-1804317 | ||
(State or Other Jurisdiction of Incorporation or Organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
Daniel S. Kim, Esq. Mitchell Zuklie, Esq. Hari Raman, Esq. Albert Vanderlaan, Esq. Orrick, Herrington & Sutcliffe LLP 631 Wilshire Boulevard Santa Monica, California 90401 Tel: (301) 633-2800 |
Thomas J. Fennimore, Chief Financial Officer 2603 Discovery Drive, Suite 100 Orlando, Florida 32826 Telephone: (407) 900-5259 |
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
☒ |
Smaller reporting company | |||||
Emerging growth company |
| ||||||||
Title of Each Class of Securities to be Registered |
Amount to be Registered(1) |
Proposed Maximum Offering Price Per Share |
Proposed Maximum Aggregate Offering Price |
Amount of Registration Fee | ||||
Class A Common Stock, par value $0.0001 per share |
194,581,139 (2) |
$26.64 (3) |
$5,183,641,542.96 |
$565,535.30 | ||||
Warrants to purchase Class A Common Stock |
6,666,666 (4) |
— (5) |
— (5) |
— (5) | ||||
Total |
$5,183,641,542.96 |
$565,535.30 | ||||||
| ||||||||
|
(1) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), there are also being registered an indeterminable number of additional shares of Class A Common Stock as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. |
(2) |
Consists of (i) 181,247,830 shares of Class A Common Stock registered for sale by the selling securityholders named in this registration statement (including the shares referred to in the following clause (ii)), (ii) 6,666,666 shares of Class A Common Stock issuable upon exercise of 6,666,666 Private Warrants (as defined below), and (iii) 13,333,309 shares of Class A Common Stock issuable upon the exercise of 13,333,309 Public Warrants (as defined below). |
(3) |
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, based upon the average of the high and low prices of the Class A common stock on December 18, 2020, as reported on The Nasdaq Stock Market LLC. |
(4) |
Represents the resale of 6,666,666 Private Warrants. |
(5) |
In accordance with Rule 457(i), the entire registration fee for the Private Warrants is allocated to the shares of Class A Common Stock underlying the Private Warrants, and no separate fee is payable for the Private Warrants. |
Page |
||||
ii |
||||
vi |
||||
1 |
||||
6 |
||||
43 |
||||
44 |
||||
45 |
||||
46 |
||||
47 |
||||
48 |
||||
59 |
||||
60 |
||||
74 |
||||
104 |
||||
112 |
||||
127 |
||||
133 |
||||
135 |
||||
139 |
||||
153 |
||||
156 |
||||
162 |
||||
162 |
||||
162 |
||||
163 |
||||
F-1 |
• | Level 1 (Driver Assistance): Vehicle is controlled by the driver, but some driving assistance features may be included. |
• | Level 2 (Partial Automation): Vehicle has combined automated functions like acceleration and steering, but the driver must remain fully engaged and monitor the driving environment at all times. |
• | Level 3 (Conditional Automation): Driver is necessary, but is not required to monitor the environment. The driver must be ready to take control of the vehicle at all times with notice. |
• | Level 4 (High Automation): The vehicle is capable of performing all driving functions under certain conditions. The driver may have the option to control the vehicle. |
• | Level 5 (Full Automation): The vehicle is capable of performing all driving functions under all conditions. The driver may have the option to control the vehicle. |
• | general economic uncertainty and the effect of general economic conditions on the Company’s industry in particular, including the level of demand and financial performance of the autonomous vehicle industry and market adoption of lidar; |
• | the Company’s history of losses and whether it will continue to incur significant expenses and continuing losses for the foreseeable future; the effect of continued pricing pressures, automotive original equipment manufacturers (“OEMs”) cost reduction initiatives and the ability of automotive OEMs to re-source or cancel vehicle or technology programs which may result in lower than anticipated margins, or losses, which may adversely affect the Company’s business; |
• | the ability of the Company to protect and enforce its intellectual property rights; |
• | whether the Company’s lidar products are selected for inclusion in autonomous driving or ADAS systems by automotive OEMs or their suppliers; |
• | the Company’s inability to reduce and control the cost of the inputs on which Luminar relies, which could negatively impact the adoption of its products and its profitability; |
• | changes in personnel and availability of qualified personnel; |
• | the effects of the ongoing coronavirus (COVID-19) pandemic or other infectious diseases, health epidemics, pandemics and natural disasters on Luminar’s business; |
• | the Company’s ability to remediate the material weakness in its internal controls over financial reporting; |
• | the Company’s ability to transition to an outsourced manufacturing business model; |
• | the Company’s anticipated investments in and results from sales and marketing and research and development (“R&D”); |
• | the success of the Company’s customers in developing and commercializing products using the Company’s solutions; |
• | the Company’s estimated total addressable market; |
• | the amount and timing of future sales; |
• | whether the complexity of the Company’s products results in undetected defects and reliability issues which could reduce market adoption of its new products, damage its reputation and expose the Company to product liability and other claims; |
• | strict government regulation that is subject to amendment, repeal or new interpretation and the Company’s ability to comply with modified or new laws and regulations applying to its business; |
• | the Company’s ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, and the ability of the Company to manage its growth and expand its business operations effectively following the consummation of the Business Combination; |
• | whether the concentration of the Company’s stock ownership and voting power limits the stockholders of the Company’s ability to influence corporate matters; and |
• | the increasingly competitive environment in which the Company operates. |
Issuer |
Luminar Technologies, Inc. (f/k/a Gores Metropoulos, Inc.). |
Shares of Class A Stock offered by us |
19,999,975 shares of Class A Stock issuable upon exercise of the Warrants, consisting of (i) 6,666,666 shares of Class A Stock that are issuable upon the exercise of 6,666,666 Private Warrants and (ii) 13,333,309 shares of Class A Stock that are issuable upon the exercise of 13,333,309 Public Warrants. |
Shares of Class A Stock outstanding prior to exercise of all Warrants |
323,936,240 shares of Class A Stock (as of December 15, 2020). |
Shares of Class A Stock outstanding assuming cash exercise of all Warrants |
343,936,215 shares of Class A Stock (as of December 15, 2020). |
Exercise Price of Private Warrants and Public Warrants |
$11.50 per share, subject to adjustments as described herein. |
Use of proceeds |
We will receive up to an aggregate of approximately $230 million from the exercise of the Warrants, assuming the exercise in full of all of the Warrants for cash. We expect to use the net proceeds from the exercise of the Warrants for general corporate purposes. See “ Use of Proceeds |
Securities offered by the Selling Securityholders |
181,247,830 shares of Class A Stock (including (i) 10,000,000 Founder Shares, (ii) 42,064,871 shares of Class A Stock issued pursuant to the Merger Agreement, (iii) 6,666,666 shares of Class A Stock issuable upon the exercise of the Private Warrants, (iv) 105,118,203 Executive Shares, (v) up to 3,944,151 Earn-Out Shares that may be issued in the form of Class A Stock pursuant to the earn-out provisions in the Merger Agreement, (vi) up 10,455,134 shares of Class A Stock that may be issued or issuable upon the conversion of any Earn-Out Shares that may be issued in the form of Class B Stock pursuant to the earn-out provisions in the Merger Agreement, and (vii) up to 2,989,805 shares of Class A Stock issuable upon the exercise of outstanding Rollover Options (as defined above) to purchase shares of Class A Stock). |
Terms of the offering |
The Selling Securityholders will determine when and how they will dispose of the shares of Class A Stock and Warrants registered under this prospectus for resale. |
Use of proceeds |
We will not receive any proceeds from the sale of shares of Class A Stock or Private Warrants (assuming the cashless exercise provision is used) by the Selling Securityholders. |
Lock-Up Restrictions |
Certain of our stockholders are subject to certain restrictions on transfer until the termination of applicable lock-up periods. See “Certain Relationships and Related Transactions—Lock-Up Agreements |
Risk Factors |
See “ Risk Factors |
Nasdaq Stock Market Symbols |
Our Class A Stock and Public Warrants are listed on the Nasdaq Global Select Market under the symbols “LAZR” and “LAZRW,” respectively. |
• | We are an early stage company with a history of losses, and we expect to incur significant expenses and continuing losses for the foreseeable future. |
• | Our limited operating history makes it difficult to evaluate our future prospects and the risks and challenges we may encounter. |
• | We continue to implement strategic initiatives designed to grow our business. These initiatives may prove more costly than we currently anticipate and we may not succeed in increasing our revenue in an amount sufficient to offset the costs of these initiatives and to achieve and maintain profitability. |
• | If our lidar products are not selected for inclusion in autonomous driving systems or ADAS by automotive OEMs or their suppliers, our business will be materially and adversely affected. |
• | Our forward looking estimates of certain financial metrics, including our Order Book (as defined below), may prove inaccurate. |
• | Information concerning our future cost of goods sold and bill of materials estimates may prove inaccurate. |
• | We are reliant on key inputs and our inability to reduce and control the cost of such inputs could negatively impact the adoption of our products and our profitability. |
• | Continued pricing pressures, automotive OEM cost reduction initiatives and the ability of automotive OEMs to re-source or cancel vehicle or technology programs may result in lower than anticipated margins, or losses, which may adversely affect our business. |
• | We expect to incur substantial R&D costs and devote significant resources to identifying and commercializing new products, which could significantly reduce our profitability and may never result in revenue to us. |
• | Although we believe that lidar is the industry standard for autonomous vehicles and other emerging markets, market adoption of lidar is uncertain. If market adoption of lidar does not continue to develop, or develops more slowly than we expect, our business will be adversely affected. |
• | We may experience difficulties in managing our growth and expanding our operations. |
• | We rely on third-party suppliers and because some of the raw materials and key components in our products come from limited or single source suppliers, we are susceptible to supply shortages, long lead times for components, and supply changes, any of which could disrupt our supply chain and could delay deliveries of our products to customers. |
• | Because our sales have been primarily to customers making purchases for R&D projects and our orders are project-based, we expect our results of operations to fluctuate on a quarterly and annual basis, which could cause our stock price to fluctuate or decline. |
• | Our transition to an outsourced manufacturing business model may not be successful, which could harm our ability to deliver products and recognize revenue. |
• | We, our outsourcing partners and our suppliers may rely on complex machinery for our production, which involves a significant degree of risk and uncertainty in terms of operational performance and costs. |
• | Our sales and operations in international markets expose us to operational, financial and regulatory risks. |
• | The complexity of our products could result in unforeseen delays or expenses from undetected defects, errors or reliability issues in hardware or software which could reduce the market adoption of our new products, damage our reputation with current or prospective customers, expose us to product liability and other claims and adversely affect our operating costs. |
• | We may be subject to product liability or warranty claims that could result in significant direct or indirect costs, which could adversely affect our business and operating results. |
• | If we do not maintain sufficient inventory or if we do not adequately manage our inventory, we could lose sales or incur higher inventory-related expenses, which could negatively affect our operating results. |
• | The average selling prices of our products could decrease rapidly over the life of the product, which may negatively affect our revenue and gross margin. |
• | Adverse conditions in the automotive industry or the global economy more generally could have adverse effects on our results of operations. |
• | The discontinuation, lack of commercial success, or loss of business with respect to a particular vehicle model or technology package for which we are a significant supplier could reduce our sales and adversely affect our profitability. |
• | Since many of the markets in which we compete are new and rapidly evolving, it is difficult to forecast long-term end-customer adoption rates and demand for our products. |
• | We currently have and target many customers that are large corporations with substantial negotiating power, exacting product standards and potentially competitive internal solutions. If we are unable to sell our products to these customers, our prospects and results of operations will be adversely affected. |
• | Our business could be materially and adversely affected if we lost any of our largest customers or if we were unable to pay our invoices. |
• | We are substantially dependent on our partnership with Volvo, and our business could be materially and adversely affected if our partnership with Volvo were terminated. |
• | We have identified material weaknesses in our internal control over financial reporting as of December 31, 2018 and 2019. If we are unable to develop and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner, which may adversely affect investor confidence in us. |
• | Our business could be materially and adversely affected by the current global COVID-19 pandemic or other health epidemics and outbreaks. |
• | Our business may be adversely affected by changes in automotive and laser regulations or concerns that drive further regulation of the automobile and laser market. |
• | The dual class structure of our common stock, par value $0.0001 per share has the effect of concentrating voting control with Austin Russell, our Founder, President and Chief Executive Officer. This will limit or preclude your ability to influence corporate matters, including the outcome of important transactions, including a change in control. |
• | continue to utilize our third-party partners for design, testing and commercialization; |
• | expand our production capabilities to produce our lidar solutions, including costs associated with outsourcing the production of our lidar solutions; |
• | expand our design, development, installation and servicing capabilities; |
• | build up inventories of parts and components for our lidar solutions; |
• | produce an inventory of our lidar solutions; and |
• | increase our sales and marketing activities and develop our distribution infrastructure. |
• | produce and deliver lidar and software products of acceptable performance; |
• | forecast our revenue and budget for and manage our expenses; |
• | attract new customers and retain existing customers; |
• | comply with existing and new or modified laws and regulations applicable to our business; |
• | plan for and manage capital expenditures for our current and future products, and manage our supply chain and supplier relationships related to our current and future products; |
• | anticipate and respond to macroeconomic changes and changes in the markets in which we operate; |
• | maintain and enhance the value of our reputation and brand; |
• | effectively manage our growth and business operations, including the impacts of the COVID-19 pandemic on our business; |
• | develop and protect intellectual property; |
• | hire, integrate and retain talented people at all levels of its organization; and |
• | successfully develop new solutions to enhance the experience of customers. |
• | investing in R&D; |
• | expanding our sales and marketing efforts to attract new customers; |
• | investing in new applications and markets for our products; |
• | further enhancing our manufacturing processes and partnerships; |
• | pursuing litigation to protect our intellectual property; and |
• | investing in legal, accounting, and other administrative functions necessary to support our operations as a public company. |
• | the extent to which customers who have selected Luminar for a program win commercially launch vehicles which include our hardware and software products; |
• | the extent to which Luminar meets contractual terms and conditions; |
• | the extent to which our technology is successfully integrated into our customers’ vehicles; |
• | the timing of when our customers adopt our technology into their vehicles on a commercial basis which could be delayed for regulatory, safety or reliability issues unrelated to our technology; |
• | undetected or unknown errors, defects or reliability issues in our hardware or software which could reduce the market adoption of our new products; |
• | loss of business with respect to, the failure or lack of commercial success of a vehicle model for which we are a significant supplier for reasons unrelated to our technology; For more information about certain risks related to discontinuation or loss of business, please see the Risk Factor on page 18 of this prospectus captioned “ The discontinuation, lack of commercial success, or loss of business with respect |
to a particular vehicle model or technology package for which we are a significant supplier could reduce our sales and adversely affect our profitability |
• | a decline, for any reason, in the production levels of our customers, particularly with respect to models which incorporate our technology; |
• | customer cancellations of their contracts; |
• | if Luminar’s products are included as part of a vehicle option package, the extent to which end customers select it; and |
• | other risk factors set forth in this prospectus. |
• | meeting certain volume estimates; |
• | our reliance on key inputs and our inability to reduce and control the cost of such inputs; |
• | our dependence on producing or sourcing certain key components and raw materials at acceptable price levels and our ability to adequately reduce and control the costs of such key components; For more information about certain risks related to our reliance on key inputs and our inability to reduce and control the costs of such inputs, please see the Risk Factor on page 10 of this prospectus captioned “ We are reliant on key inputs and our ability to reduce and control the cost of such inputs could negatively impact the adoption of our products and our profitability |
• | the risk of shortages and long lead times in the supply of key components and the risk that our suppliers discontinue or modify components used in its products; For more information about certain risks related to reliance on third party suppliers, please see the Risk Factor on page 12 of this prospectus captioned “ We rely on third-party suppliers and because some of the raw materials and key components in our products come from limited or single source suppliers, we are susceptible to supply shortages, long lead times for components, and supply changes, any of which could disrupt our supply chain and could delay deliveries of our products to customers |
• | lack of consistency and adequate quality and quantity of piece parts, other raw materials and other bill of materials items; |
• | contract negotiations and the execution of firm supply agreements; |
• | future versions of our product design incorporating new components meeting our customers’ requirements and specifications. For more information about certain risks related to product selection, please see the Risk Factor on page 20 of this prospectus captioned “ The period of time from a design win to implementation is long and we are subject to the risks of cancellation or postponement of the contract or unsuccessful implementation |
• | the qualification of new versions of our key components. For more information about certain risks related to qualification, please see the Risk Factor on page 8 of this prospectus captioned “ If our lidar products are not selected for inclusion in autonomous driving systems or ADAS by automotive OEMs or their suppliers, our business will be materially and adversely affected |
• | defects in production processes (including system assembly) either within our facilities or at our suppliers; |
• | any transitions or changes in our production process, planned or unplanned; and |
• | other risk factors set forth in this prospectus. |
• | the timing and magnitude of orders and shipments of our products in any quarter; |
• | pricing changes we may adopt to drive market adoption or in response to competitive pressure; |
• | our ability to retain our existing customers and attract new customers; |
• | our ability to develop, introduce, manufacture and ship in a timely manner products that meet customer requirements; |
• | disruptions in our sales channels or termination of its relationship with important channel partners; |
• | delays in customers’ purchasing cycles or deferments of customers’ purchases in anticipation of new products or up-dates from us or our competitors; |
• | fluctuations in demand pressures for our products; |
• | the mix of products sold in any quarter; |
• | the duration of the global COVID-19 pandemic and the time it takes for economic recovery; |
• | the timing and rate of broader market adoption of autonomous systems utilizing our solutions across the automotive and other market sectors; |
• | market acceptance of lidar and further technological advancements by our competitors and other market participants; |
• | the ability of our customers to commercialize systems that incorporate our products; |
• | any change in the competitive dynamics of our markets, including consolidation of competitors, regulatory developments and new market entrants; |
• | our ability to effectively manage our inventory; |
• | changes in the source, cost, availability of and regulations pertaining to materials we use; |
• | adverse litigation, judgments, settlements or other litigation-related costs, or claims that may give rise to such costs; and |
• | general economic, industry and market conditions, including trade disputes. |
• | foreign currency fluctuations; |
• | local economic conditions; |
• | political instability; |
• | import or export requirements; |
• | foreign government regulatory requirements; |
• | reduced protection for intellectual property rights in some countries; |
• | tariffs and other trade barriers and restrictions; and |
• | potentially adverse tax consequences. |
• | exchange rate fluctuations; |
• | political and economic instability, international terrorism and anti-American sentiment, particularly in emerging markets; |
• | global or regional health crises, such as the COVID-19 pandemic or other health epidemics and outbreaks; |
• | potential for violations of anti-corruption laws and regulations, such as those related to bribery and fraud; |
• | preference for locally branded products, and laws and business practices favoring local competition; |
• | potential consequences of, and uncertainty related to, the “Brexit” process in the United Kingdom, which could lead to additional expense and complexity in doing business there; |
• | increased difficulty in managing inventory; |
• | delayed revenue recognition; |
• | less effective protection of intellectual property; |
• | stringent regulation of the autonomous or other systems or products using our products and stringent consumer protection and product compliance regulations, including but not limited to General Data Protection Regulation in the European Union, European competition law, the Restriction of Hazardous Substances Directive, the Waste Electrical and Electronic Equipment Directive and the European Ecodesign Directive that are costly to comply with and may vary from country to country; |
• | difficulties and costs of staffing and managing foreign operations; |
• | import and export laws and the impact of tariffs; |
• | changes in local tax and customs duty laws or changes in the enforcement, application or interpretation of such laws; and |
• | U.S. government’s restrictions on certain technology transfer to certain countries of concern. |
• | identify, select and apply GAAP sufficiently to provide reasonable assurance that transactions were being appropriately recorded; and |
• | assess risk and design appropriate control activities over information technology systems and financial and reporting processes necessary to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements. |
• | changes in tax laws or the regulatory environment; |
• | changes in accounting and tax standards or practices; |
• | changes in the composition of operating income by tax jurisdiction; and |
• | our operating results before taxes. |
• | changes in the valuation of our deferred tax assets and liabilities; |
• | expected timing and amount of the release of any tax valuation allowances; |
• | tax effects of stock-based compensation; |
• | costs related to intercompany restructurings; |
• | changes in tax laws, regulations or interpretations thereof; or |
• | lower than anticipated future earnings in jurisdictions where we have lower statutory tax rates and higher than anticipated future earnings in jurisdictions where we have higher statutory tax rates. |
• | providing for a classified board of directors with staggered, three-year terms; |
• | authorizing our Board to issue Preferred Stock with voting or other rights or preferences that could discourage a takeover attempt or delay changes in control; |
• | prohibiting cumulative voting in the election of directors; |
• | providing that vacancies on our Board may be filled only by a majority of directors then in office, even though less than a quorum; |
• | prohibiting the adoption, amendment or repeal of the Amended and Restated Bylaws or the repeal of the provisions of our Second Amended and Restated Certificate of Incorporation regarding the election and removal of directors without the required approval of at least two-thirds of the shares entitled to vote at an election of directors; |
• | prohibiting stockholder action by written consent; |
• | limiting the persons who may call special meetings of stockholders; and |
• | requiring advance notification of stockholder nominations and proposals. |
• | we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful; |
• | we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law; |
• | we will be required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if we are ultimately determined that such person is not entitled to indemnification; |
• | we will not be obligated pursuant to our Amended and Restated Bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our Board or brought to enforce a right to indemnification; |
• | the rights conferred in the Amended and Restated Bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and |
• | we may not retroactively amend our Amended and Restated Bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents. |
• | the realization of any of the risk factors presented in this prospectus; |
• | actual or anticipated differences in our estimates, or in the estimates of analysts, for our revenues, Adjusted EBITDA, results of operations, level of indebtedness, liquidity or financial condition; |
• | additions and departures of key personnel; |
• | failure to comply with the requirements of Nasdaq; |
• | failure to comply with the Sarbanes-Oxley Act or other laws or regulations; |
• | future issuances, sales, resales or repurchases or anticipated issuances, sales, resales or repurchases, of our securities; |
• | publication of research reports about us; |
• | the performance and market valuations of other similar companies; |
• | commencement of, or involvement in, litigation involving us; |
• | broad disruptions in the financial markets, including sudden disruptions in the credit markets; |
• | speculation in the press or investment community; |
• | actual, potential or perceived control, accounting or reporting problems; |
• | changes in accounting principles, policies and guidelines; and |
• | other events or factors, including those resulting from infectious diseases, health epidemics and pandemics (including the ongoing COVID-19 public health emergency), natural disasters, war, acts of terrorism or responses to these events. |
(in thousands, except per share data) |
As of and for the Nine Months Ended September 30, 2020 |
As of and for the Nine Months Ended September 30, 2019 |
As of and for the year ended December 31, 2019 |
As of and for the year ended December 31, 2018 |
||||||||||||
Statement of Income Data: |
||||||||||||||||
Net sales |
$ | 11,519 | $ | 6,803 | $ | 12,602 | $ | 11,692 | ||||||||
Total operating expenses |
49,791 | 42,425 | 58,562 | 64,982 | ||||||||||||
Net loss |
(72,227 | ) | (76,774 | ) | (94,718 | ) | (79,550 | ) | ||||||||
Net loss per share attributable to common stockholders—Basic and diluted |
(8.25 | ) | (9.46 | ) | (11.47 | ) | (12.00 | ) | ||||||||
Balance Sheet Data: |
||||||||||||||||
Total assets |
191,453 | N/A | 51,864 | 28,202 | ||||||||||||
Total liabilities |
61,837 | N/A | 18,851 | 152,869 | ||||||||||||
Total mezzanine equity |
408,854 | N/A | 244,743 | — | ||||||||||||
Total stockholders’ deficit |
(279,238 | ) | N/A | (211,730 | ) | (124,667 | ) |
For the Nine Months Ended September 30, 2020 (unaudited) |
For the Nine Months Ended September 30, 2019 (unaudited) |
For the Year Ended December 31, 2019 (audited) |
For the Period from August 28, 2018 (inception) to December 31, 2018 |
|||||||||||||
Professional fees and other expenses |
$ | (4,408,626 | ) | $ | (460,780 | ) | $ | (620,871 | ) | $ | (20,554 | ) | ||||
State franchise taxes, other than income tax |
(150,000 | ) | (150,000 | ) | (200,000 | ) | (1,431 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Loss from operations |
(4,558,626 | ) | (610,780 | ) | (820,871 | ) | (21,985 | ) | ||||||||
Other income—interest income |
1,351,950 | 6,005,266 | 7,707,654 | — | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net income/(loss) before income taxes |
$ | (3,206,676 | ) | $ | 5,394,486 | $ | 6,886,783 | $ | (21,985 | ) | ||||||
|
|
|
|
|
|
|
|
|||||||||
Provision for income tax |
(171,781 | ) | (1,132,843 | ) | (1,441,607 | ) | — | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Net income/(loss) attributable to common shares |
$ | (3,378,457 | ) | $ | 4,261,643 | $ | 5,445,176 | $ | (21,985 | ) | ||||||
|
|
|
|
|
|
|
|
|||||||||
Net income/(loss) per ordinary share: |
||||||||||||||||
Class A ordinary shares—basic and diluted |
$ | (0.06 | ) | $ | 0.13 | $ | 0.16 | $ | — | |||||||
|
|
|
|
|
|
|
|
|||||||||
Class F ordinary shares—basic and diluted |
$ | (0.09 | ) | $ | (0.04 | ) | $ | (0.05 | ) | $ | 0 | |||||
|
|
|
|
|
|
|
|
Balance Sheet Data |
September 30, 2020 (unaudited) |
December 31, 2019 (audited) |
December 31, 2018 (audited) |
|||||||||
Total assets |
$ | 406,303,529 | 407,938,951 | 489,864 | ||||||||
Total liabilities |
17,098,900 | 15,355,865 | 486,849 | |||||||||
Value of Class A Common Stock subject to possible redemption |
384,204,620 | 387,134,760 | 0 | |||||||||
Total stockholders’ equity |
5,000,009 | 5,448,326 | 3,015 |
(in thousands, except for per share amounts) |
||||
Shares transferred at Closing (1) |
294,268,645 | |||
Value per share (2) |
$ | 10.00 | ||
|
|
|||
Total Share Consideration |
$ | 2,942,686 | ||
|
|
(1) | The number of outstanding shares in the table above assumes the issuance of approximately 20,313,754 shares of Class A Stock underlying Rollover Options and Assumed Warrants that do not represent legally outstanding shares of Class A Stock at Closing. |
(2) | Share Consideration is calculated using a $10.00 reference price. The closing share price on the date of the consummation of the Business Combination was $18.00. As the Business Combination was accounted for as a reverse recapitalization, the value per share is disclosed for informational purposes only in order to indicate the fair value of shares transferred. |
Shares |
% |
|||||||
Luminar Class A Stock (1), (2), (3) |
168,836,688 | 52.1 | % | |||||
Luminar Class B Stock (1), (4) |
105,118,203 | 32.5 | % | |||||
Public Shares |
39,981,349 | 12.3 | % | |||||
Founders Class A Stock |
10,000,000 | 3.1 | % | |||||
|
|
|
|
|||||
Pro Forma common stock |
323,936,240 |
100 |
% | |||||
|
|
|
|
(1) | Excludes approximately 15,363,611 of Class A Stock and 10,455,134 of Class B Stock in potential earn out shares as the price threshold for each tranche have not yet been triggered. |
(2) | Includes the issuance of 1,354,072 shares of Luminar Series X preferred stock in August, September, and October 2020 that converted into approximately 18,457,231 shares of Class A Stock upon the Closing. |
(3) | The number of outstanding shares in the table above does not assume the issuance of approximately 20,313,754 shares of Class A Stock underlying Rollover Options and Assumed Warrants that do not represent legally outstanding shares of Class A Stock at Closing. |
(4) | Class B Stock carry ten votes per share whereas Class A Stock will have one vote per share. |
As of September 30, 2020 |
As of September 30, 2020 |
|||||||||||||||||||||||||||
Luminar (Historical) |
Luminar Pro Forma Adjustments |
Luminar As Adjusted |
Gores (Historical) |
Pro Forma Adjustments |
Pro Forma Combined |
|||||||||||||||||||||||
ASSETS |
||||||||||||||||||||||||||||
Current assets: |
||||||||||||||||||||||||||||
Cash and cash equivalents |
$ | 50,700 | $ | 13,864 | (A) | $ | 64,564 | $ | 519 | $ | 405,725 | (B) | $ | 387,112 | ||||||||||||||
(1,891 | ) | (C) | ||||||||||||||||||||||||||
(49,854 | ) | (D) | ||||||||||||||||||||||||||
(31,762 | ) | (J) | ||||||||||||||||||||||||||
(189 | ) | (K) | ||||||||||||||||||||||||||
Restricted cash and cash equivalents |
225 | — | 225 | — | — | 225 | ||||||||||||||||||||||
Marketable securities |
117,130 | — | 117,130 | — | — | 117,130 | ||||||||||||||||||||||
Accounts receivable, net |
955 | — | 955 | — | — | 955 | ||||||||||||||||||||||
Inventories, net |
2,921 | — | 2,921 | — | — | 2,921 | ||||||||||||||||||||||
Prepaids and other current assets |
9,771 | — | 9,771 | 60 | (4,603 | ) | (D) | 5,228 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Total current assets |
181,702 | 13,864 | 195,566 | 579 | 317,426 | 513,571 | ||||||||||||||||||||||
Non-current assets: |
||||||||||||||||||||||||||||
Investments and cash held in Trust Account |
— | — | — | 405,725 | (405,725 | ) | (B) | — | ||||||||||||||||||||
Property and equipment, net |
7,765 | — | 7,765 | — | — | 7,765 | ||||||||||||||||||||||
Goodwill |
701 | — | 701 | — | — | 701 | ||||||||||||||||||||||
Other long-term assets |
1,285 | — | 1,285 | — | — | 1,285 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Total non-current assets |
9,751 | — | 9,751 | 405,725 | (405,725 | ) | 9,751 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
TOTAL ASSETS |
$ |
191,453 |
$ |
13,864 |
$ |
205,317 |
$ |
406,304 |
$ |
(88,299 |
) |
$ |
523,322 |
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||||||||||||||||||||||
Accounts payable |
8,250 | — | 8,250 | — | (2,896 | ) | (D) | 5,354 | ||||||||||||||||||||
Accrued expenses and other current liabilities |
7,667 | — | 7,667 | 2,936 | (1,861 | ) | (C) | 5,456 | ||||||||||||||||||||
(3,286 | ) | (D) | ||||||||||||||||||||||||||
State franchise tax accrual |
— | — | — | 30 | (30 | ) | (C) | — | ||||||||||||||||||||
Current portion of long-term debt |
1,949 | 1,949 | — | (1,949 | ) | (J) | — | |||||||||||||||||||||
Other current liabilities |
442 | — | 442 | 133 | — | 575 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Total current liabilities |
18,308 | — | 18,308 | 3,099 | (10,022 | ) | 11,385 |
As of September 30, 2020 |
As of September 30, 2020 |
|||||||||||||||||||||||||||
Luminar (Historical) |
Luminar Pro Forma Adjustments |
Luminar As Adjusted |
Gores (Historical) |
Pro Forma Adjustments |
Pro Forma Combined |
|||||||||||||||||||||||
Non-current liabilities: |
||||||||||||||||||||||||||||
Deferred underwriting compensation |
— | — | — | 14,000 | (14,000 | ) | (D) | — | ||||||||||||||||||||
Long-term debt |
26,877 | — | 26,877 | — | (26,877 | ) | (J) | — | ||||||||||||||||||||
Warrant liabilities |
15,412 | — | 15,412 | — | (15,412 | ) | (E) | — | ||||||||||||||||||||
Other long-term liabilities |
1,240 | — | 1,240 | — | — | 1,240 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Total non-current liabilities |
43,529 | — | 43,529 | 14,000 | (56,289 | ) | 1,240 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Total liabilities |
61,837 | — | 61,837 | 17,099 | (66,311 | ) | 12,625 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Common stock subject to possible redemption |
— | — | — | 384,205 | (384,205 | ) | (F) | — | ||||||||||||||||||||
Series A preferred stock |
244,743 | — | 244,743 | — | (244,743 | ) | (G) | — | ||||||||||||||||||||
Series X preferred stock |
164,111 | 13,864 | (A) | 177,975 | — | (177,975 | ) | (G) | — | |||||||||||||||||||
Stockholders’ equity (deficit): |
||||||||||||||||||||||||||||
Preferred stock |
— | — | — | — | — | — | ||||||||||||||||||||||
Founders’ preferred stock |
— | — | — | — | — | — | ||||||||||||||||||||||
Common stock |
— | — | — | — | — | |||||||||||||||||||||||
Class A Common Stock |
— | — | — | — | 4 | (F) | 22 | |||||||||||||||||||||
17 | (G) | |||||||||||||||||||||||||||
1 | (H) | |||||||||||||||||||||||||||
— | (K) | |||||||||||||||||||||||||||
Class B Common Stock |
— | — | — | — | 11 | (G) | 11 | |||||||||||||||||||||
Class F Common Stock |
— | — | — | 1 | (1 | ) | (H) | — | ||||||||||||||||||||
Additional paid-in capital |
15,212 | — | 15,212 | 2,954 | (27,329 | ) | (D) | 814,996 | ||||||||||||||||||||
15,412 | (E) | |||||||||||||||||||||||||||
384,201 | (F) | |||||||||||||||||||||||||||
422,690 | (G) | |||||||||||||||||||||||||||
2,045 | (I) | |||||||||||||||||||||||||||
(189 | ) | (K) | ||||||||||||||||||||||||||
Treasury stock |
— | — | — | — | — | — | ||||||||||||||||||||||
Accumulated other comprehensive loss |
(20 | ) | — | (20 | ) | — | — | (20 | ) | |||||||||||||||||||
Retained earnings/(accumulated deficit) |
(294,430 | ) | — | (294,430 | ) | 2,045 | (6,946 | ) | (D) | (304,312 | ) | |||||||||||||||||
(2,045 | ) | (I) | ||||||||||||||||||||||||||
(2,936 | ) | (J) | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Total stockholders’ equity (deficit) |
(279,238 | ) | — | (279,238 | ) | 5,000 | 784,935 | 510,697 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) |
$ |
191,453 |
$ |
13,864 |
$ |
205,317 |
$ |
406,304 |
$ |
(88,299 |
) |
$ |
523,322 |
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine Months Ended September 30, 2020 |
For the Nine Months Ended September 30, 2020 |
|||||||||||||||||||
Luminar (Historical) |
Gores (Historical) |
Pro Forma Adjustments |
Pro Forma Combined |
|||||||||||||||||
Net sales |
$ | 11,519 | $ | — | $ | — | $ | 11,519 | ||||||||||||
Cost of sales |
18,209 | — | — | 18,209 | ||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Gross loss |
(6,690 | ) | — | — | (6,690 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Operating expenses: |
||||||||||||||||||||
Selling and marketing expenses |
5,407 | — | — | 5,407 | ||||||||||||||||
General and administrative expenses |
16,116 | — | (1,764 | ) | (EE | ) | 14,352 | |||||||||||||
Research and development expenses |
28,268 | — | — | 28,268 | ||||||||||||||||
State franchise taxes, other than income tax |
— | 150 | — | 150 | ||||||||||||||||
Other operating expenses |
— | 4,409 | (1,075 | ) | (EE | ) | 3,334 | |||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Total operating expenses |
49,791 | 4,559 | (2,839 | ) | 51,511 | |||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Operating loss |
(56,481 | ) | (4,559 | ) | 2,839 | (58,201 | ) | |||||||||||||
Interest income |
162 | 1,352 | (1,352 | ) | (AA | ) | 162 | |||||||||||||
Interest expense |
(2,097 | ) | — | 2,044 | (CC | ) | (53 | ) | ||||||||||||
Changes in fair values of warrant liabilities |
(12,562 | ) | — | 12,562 | (BB | ) | — | |||||||||||||
Loss on extinguishment of debt |
(866 | ) | — | — | (866 | ) | ||||||||||||||
Other income |
10 | — | — | 10 | ||||||||||||||||
Other expense |
(393 | ) | — | — | (393 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Income (loss) before income taxes |
(72,227 | ) | (3,207 | ) | 16,093 | (59,341 | ) | |||||||||||||
Provision for (benefit from) income taxes |
— | 172 | (172 | ) | (DD | ) | — | |||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Net income (loss) attributable to common stockholders |
$ | (72,227 | ) | $ | (3,379 | ) | $ | 16,265 | $ | (59,341 | ) | |||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Weighted average shares outstanding - Common stock |
9,510,996 | |||||||||||||||||||
Common stock - basic and diluted |
$ | (8.25 | ) | |||||||||||||||||
Weighted average shares outstanding - Class A Common Stock |
40,000,000 | 218,818,037 | ||||||||||||||||||
Class A Common Stock - basic and diluted |
$ | (0.06 | ) | $ | (0.18 | ) | ||||||||||||||
Weighted average shares outstanding - Class F Common Stock |
10,000,000 | |||||||||||||||||||
Class F Common Stock - basic and diluted |
$ | (0.09 | ) | |||||||||||||||||
Weighted average shares outstanding - Class B Common Stock |
105,118,203 | |||||||||||||||||||
Class B Common Stock - basic and diluted |
$ | (0.18 | ) |
For the Year ended December 31, 2019 |
Pro Forma Adjustments |
For the Year ended December 31, 2019 |
||||||||||||||||||
Luminar (Historical) |
Gores (Historical) |
Pro Forma Combined |
||||||||||||||||||
Net sales |
$ | 12,602 | $ | — | $ | — | $ | 12,602 | ||||||||||||
Cost of sales |
16,655 | — | — | 16,655 | ||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Gross loss |
(4,053 | ) | — | — | (4,053 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Operating expenses: |
||||||||||||||||||||
Selling and marketing expenses |
4,730 | — | — | 4,730 | ||||||||||||||||
General and administrative expenses |
16,861 | — | — | 16,861 | ||||||||||||||||
Research and development expenses |
36,971 | — | — | 36,971 | ||||||||||||||||
State franchise taxes, other than income tax |
— | 200 | — | 200 | ||||||||||||||||
Other operating expenses |
— | 621 | — | 621 | ||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Total operating expenses |
58,562 | 821 | — | 59,383 | ||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Operating loss |
(62,615 | ) | (821 | ) | — | (63,436 | ) | |||||||||||||
Interest income |
509 | 7,708 | (7,708 | ) | (AA | ) | 509 | |||||||||||||
Interest expense |
(2,239 | ) | — | 2,216 | (CC | ) | (23 | ) | ||||||||||||
Change in fair value of SAFE notes |
(24,215 | ) | — | — | (24,215 | ) | ||||||||||||||
Changes in fair values of warrant liabilities |
(256 | ) | — | 256 | (BB | ) | — | |||||||||||||
Loss on extinguishment of debt |
(6,124 | ) | — | — | (6,124 | ) | ||||||||||||||
Other income |
262 | — | — | 262 | ||||||||||||||||
Other expense |
(40 | ) | — | — | (40 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Income (loss) before income taxes |
(94,718 | ) | 6,887 | (5,236 | ) | (93,067 | ) | |||||||||||||
Provision for (benefit from) income taxes |
— | 1,442 | (1,442 | ) | (DD | ) | — | |||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Net income (loss) attributable to common stockholders |
$ | (94,718 | ) | $ | 5,445 | $ | (3,794 | ) | $ | (93,067 | ) | |||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Weighted average shares outstanding - Common stock |
8,718,104 | |||||||||||||||||||
Common stock - basic and diluted |
$ | (11.47 | ) | |||||||||||||||||
Weighted average shares outstanding - Class A Common Stock |
36,164,000 | 218,818,037 | ||||||||||||||||||
Class A Common Stock - basic and diluted |
$ | 0.16 | $ | (0.29 | ) | |||||||||||||||
Weighted average shares outstanding - Class F Common Stock |
10,162,656 | |||||||||||||||||||
Class F Common Stock - basic and diluted |
$ | (0.05 | ) | |||||||||||||||||
Weighted average shares outstanding - Class B Common Stock |
105,118,203 | |||||||||||||||||||
Class B Common Stock - basic and diluted |
$ | (0.29 | ) |
1. |
Basis of Presentation |
• | The Company’s unaudited balance sheet as of September 30, 2020 and the related notes as of September 30, 2020, incorporated by reference; |
• | Legacy Luminar’s unaudited consolidated balance sheet as of September 30, 2020 and the related notes as of September 30, 2020, included elsewhere in this prospectus. |
• | The Company’s unaudited statement of operations for the nine months ended September 30, 2020 and the related notes, incorporated by reference; and |
• | Legacy Luminar’s unaudited statement of income for the nine months ended September 30, 2020 and the related notes, included elsewhere in this prospectus. |
• | The Company’s audited statement of operations for the twelve months ended December 31, 2019 and the related notes, incorporated by reference; and |
• | Legacy Luminar’s audited statement of income for the twelve months ended December 31, 2019 and the related notes, incorporated by reference. |
2. |
Accounting Policies |
3. |
Adjustments to Unaudited Pro Forma Condensed Combined Financial Information |
(A) | Reflects the issuance of 102,099 shares of Luminar Series X preferred stock in October 2020 at a price of $135.786 per share, and proceeds of $13.9 million. Upon the Closing, Luminar Series X preferred stock converted into the right to receive Class A Stock at an exchange ratio of approximately 13.6309. |
(B) | Reflects the reclassification of $405.7 million of cash and cash equivalents held in the Trust Account at the balance sheet date that becomes available to fund the Business Combination. |
(C) | Reflects the settlement of the Company’s historical liabilities that were settled upon the Closing. |
(D) | Represents transaction costs totaling $51.1 million, consisting of approximately $47.0 million of equity issuance costs. Classification of transaction costs is as follows: |
(in thousands) |
Amount |
|||
Costs related to issuance of equity |
||||
Deferred underwriting fees |
$ | 14,000 | ||
Series X equity issuance costs |
5,662 | |||
Amounts previously capitalized and paid |
707 | |||
Amounts previously capitalized but not paid |
3,896 | |||
Amounts incurred as part of the transaction |
22,726 | |||
|
|
|||
Subtotal |
$ | 46,991 | ||
Transaction expenses |
||||
Amounts incurred and paid |
$ | 553 | ||
Amounts incurred and not paid |
2,286 | |||
Amounts incurred as part of the transaction |
1,284 | |||
|
|
|||
Subtotal |
4,123 | |||
|
|
|||
Grand Total |
$ |
51,114 |
||
|
|
(E) | Represents the reclassification of Legacy Luminar warrants from liability to equity classification as a result of the Business Combination. |
(F) | Reflects the reclassification of approximately $384.2 million of Class A Common Stock subject to possible redemption to permanent equity. |
(G) | Represents recapitalization of Legacy Luminar equity and issuance of 168,836,688 of the post-combination Company’s Class A Common Stock (inclusive of the Series X preferred stock noted in Adjustment A) and 105,118,203 of the post-combination Company’s Class B Common Stock to holders of Legacy Luminar Class A Common Stock and Legacy Luminar Class B Common Stock, respectively, as consideration for the Business Combination. |
(H) | Reflects the conversion of Class F Stock to Class A Stock. In connection with the Closing, all shares of Class F Stock were converted into shares of Class A Stock. |
(I) | Reflects the reclassification of Gores historical retained earnings. A portion of the historical retained earnings balance includes a reclassification of transaction costs that were previously expensed by Gores but have subsequently been determined to be equity issuance costs. |
(J) | Reflects the repayment of Legacy Luminar outstanding indebtedness, including settlement of unamortized discounts, in accordance with the Merger Agreement, as cash and cash equivalents exceeded $300.0 million. Additionally, this adjustment reflects an estimated prepayment penalty of $1.8 million. |
(K) | Reflects redemptions of 18,651 shares of the Company’s Class A Stock in December 2020 for approximately $0.2 million at a redemption price of $10.14 per share based on a pro forma redemption date of September 30, 2020. As of the actual redemption date, the redemption price was $10.16 per share. |
(AA) | Reflects the elimination of interest income on the Trust Account. |
(BB) | Reflects the elimination of the impact of change in fair value of warrant liabilities as the warrants are expected to become equity-classified as a result of the recapitalization, and therefore will not be marked to market at each reporting period. |
(CC) | Reflects the elimination of interest expense related to outstanding debt for the nine months ended September 30, 2020 and for the year ended December 31, 2019 as the balances were repaid at the closing of the Business Combination. |
(DD) | Reflects elimination of income tax expense as a result of elimination of the Trust Account income (noted in footnote AA). |
(EE) | Reflects the elimination of transaction costs incurred and recorded by Gores and Legacy Luminar during the nine months ended September 30, 2020. |
5. |
Loss per Share |
(in thousands, except share and per share data) |
For the Nine Months Ended September 30, 2020 |
For the Year ended December 31, 2019 |
||||||
Pro forma net loss |
$ | (59,341 | ) | $ | (93,067 | ) | ||
Weighted average shares outstanding of Class A Common Stock |
218,818,037 | 218,818,037 | ||||||
Net loss per share (Basic and Diluted) attributable to Class A stockholders (1), (2), (3) |
$ | (0.18 | ) | $ | (0.29 | ) | ||
Weighted average shares outstanding of Class B Common Stock |
105,118,203 | 105,118,203 | ||||||
Net loss per share (Basic and Diluted) attributable to Class B stockholders (2), (3) |
$ | (0.18 | ) | $ | (0.29 | ) |
(1) | Excludes approximately 20,313,754 shares of Class A Stock underlying Rollover Options and Assumed Warrants that do not represent legally outstanding shares of Class A Stock at Closing. |
(2) | For the purposes of applying the if converted method for calculating diluted earnings per share, it was assumed that all outstanding warrants sold in the IPO and the private placement are exchanged to common stock. However, since this results in anti-dilution, the effect of such exchange was not included in calculation of diluted loss per share. |
(3) | Net loss is allocated proportionally to each class of share based on the total shares outstanding per class divided by the total shares outstanding for all classes. |
• | each of Gores and Legacy Luminar on an unaudited, historical basis; |
• | the Company on a pro forma basis after giving effect to the Business Combination; and |
• | the Company on a pro forma basis after giving effect to the Business Combination and as further adjusted to give effect to the exercise of the 13,333,309 Public Warrants and the 6,666,666 Private Warrants for an aggregate of 19,999,975 shares of Class A Stock at an exercise price of $11.50 per Warrant. |
September 30, 2020 |
||||||||||||||||||||
Historical |
Pro Forma Combined |
Pro Forma As adjusted giving effect to exercise of warrants |
||||||||||||||||||
(in thousands) |
Gores |
Luminar |
||||||||||||||||||
Cash and cash equivalents |
$ | 519 | $ | 50,700 | $ | 387,112 | $ | 617,112 | 1 | |||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Investment held in Trust Account |
$ | 405,725 | $ | — | $ | — | — | |||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Debt (1) |
||||||||||||||||||||
Total Debt |
$ | — | $ | 28,826 | $ | — | — | |||||||||||||
Commitments: |
||||||||||||||||||||
Common Stock subject to possible redemption |
384,205 | — | 0 | — | ||||||||||||||||
Redeemable convertible preferred stock |
— | 408,854 | — | — | ||||||||||||||||
Equity: |
||||||||||||||||||||
Preferred Stock |
— | — | — | — | ||||||||||||||||
Common Stock |
1 | — | 33 | 35 | 2 | |||||||||||||||
Accumulated other comprehensive loss |
— | (20 | ) | (20 | ) | (20 | ) | |||||||||||||
Additional paid-in capital |
2,954 | 15,212 | 814,996 | 1,044,994 | 2 | |||||||||||||||
Retained earnings (accumulated deficit) |
2,045 | (294,430 | ) | (304,312 | ) | (304,312 | ) | |||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Total stockholders’ equity (deficit) |
5,000 | (279,238 | ) | 510,697 | $ | 740,697 | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
Total capitalization |
$ | 389,205 | $ | 129,616 | $ | 510,697 | $ | 740,697 | ||||||||||||
|
|
|
|
|
|
|
|
1 | The increase on an as adjusted basis consists of proceeds from the expected exercise of the 19,999,975 Warrants for 19,999,975 shares of Class A Stock of the Company |
2 | The increase on an adjusted basis consists of 19,999,975 shares of Class A Stock to be issued on exercise of the Warrants |
• | Personnel-related expenses, including salaries, benefits, and stock-based compensation expense, for personnel in Luminar’s research and engineering functions; |
• | Expenses related to materials, software licenses, supplies and third-party services; |
• | Prototype expenses; |
• | An allocated portion of facility and IT costs and depreciation; and |
• | Other Component Sales services provided to Luminar are accounted for as R&D by Luminar. |
Nine Month ended September 30, |
Change |
Change |
||||||||||||||
2020 |
2019 |
$ |
% |
|||||||||||||
Net sales |
$ | 11,519 | $ | 6,803 | 4,716 | 69 | % | |||||||||
Cost of sales |
18,209 | 9,346 | 8,863 | 95 | % | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Gross loss |
(6,690 | ) | (2,543 | ) | (4,147 | ) | 163 | % | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Selling and marketing expenses |
5,407 | 3,305 | 2,102 | 64 | % | |||||||||||
General and administrative expenses |
16,116 | 11,744 | 4,372 | 37 | % | |||||||||||
Research and development expenses |
28,268 | 27,376 | 892 | 3 | % | |||||||||||
Operating loss |
(56,481 | ) | (44,968 | ) | (11,513 | ) | 26 | % | ||||||||
Interest income |
162 | 265 | (103 | ) | -39 | % | ||||||||||
Interest expense |
(2,097 | ) | (1,762 | ) | (335 | ) | 19 | % | ||||||||
Change in fair value of SAFE notes |
— | (24,215 | ) | 24,215 | -100 | % | ||||||||||
Change in fair values of warrant liabilities |
(12,562 | ) | (164 | ) | (12,398 | ) | 7,553 | % | ||||||||
Loss on extinguishment of debt |
(866 | ) | (6,124 | ) | 5,258 | -86 | % | |||||||||
Other income |
10 | 234 | (224 | ) | nm | |||||||||||
Other expense |
(393 | ) | (40 | ) | (353 | ) | nm | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Loss before income taxes |
(72,227 | ) | (76,774 | ) | 4,547 | -6 | % | |||||||||
Income taxes |
— | — | — | — | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss |
$ | (72,227 | ) | $ | (76,774 | ) | 4,547 | -6 | % | |||||||
|
|
|
|
|
|
|
|
Nine Months Ended September 30, |
Change |
Change |
||||||||||||||
(in thousands, except percentages) |
2020 |
2019 |
$ |
% |
||||||||||||
Net Sales: |
||||||||||||||||
Autonomy Solutions |
$ | 9,587 | $ | 4,373 | 5,214 | 119 | % | |||||||||
Other Component Sales |
1,932 | 2,430 | (498 | ) | -20 | % |
Nine Months Ended September 30, |
Change |
Change |
||||||||||||||
(in thousands, except percentages) |
2020 |
2019 |
$ |
% |
||||||||||||
Segment loss |
||||||||||||||||
Autonomy Solutions |
$ | (56,673 | ) | $ | (45,235 | ) | (11,438 | ) | 25 | % | ||||||
Other Component Sales |
192 | 267 | (75 | ) | -28 | % |
Nine months ended September 30, |
||||||||
(in thousands) |
2020 |
2019 |
||||||
Net cash provided by (used in): |
||||||||
Operating activities |
$ | (47,731 | ) | $ | (45,398 | ) | ||
Investing activities |
$ | (112,453 | ) | $ | (754 | ) | ||
Financing activities |
$ | 183,804 | $ | 88,085 |
• | Expected Term—Luminar uses the simplified method when calculating the expected term due to insufficient historical exercise data. |
• | Expected Volatility—As Luminar’s stock was not publicly traded prior to the Business Combination, the volatility is based on a benchmark of comparable companies within the automotive and energy storage industries. |
• | Expected Dividend Yield—The dividend rate used is zero as Luminar has never paid any cash dividends on its common stock and does not anticipate doing so in the foreseeable future. |
• | Risk-Free Interest Rate—The interest rates used are based on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term equal to the expected life of the award. |
• | Our partnership with the largest global truck OEM to pursue a common goal of bringing series produced, highly automated trucks (SAE L4) to roads globally accelerates our leadership position in trucking autonomy. We have now partnered with nearly all major programs for long-haul highway automation. |
• | We executed exclusive supply agreements for all three of our key lidar components (receiver, ASIC, and laser), locking in an estimated sub $100 hardware cost in volume. |
• | We are concluding a Contract Manufacturer selection process for series production of Iris and we have selected our lead partner and factory in Mexico. |
• | We are on-track for powering series production vehicles in 2022 by delivering key milestone of Iris B-samples and shipping to our lead series production partner Volvo Cars. |
• | We increased our target year-end 2020 Order Book from $1 billion to approximately $1.3 billion, due to new agreements with OEMs and increased existing customer volume outlook. “Order Book” is defined as the forward-looking cumulative sales estimates of Luminar’s hardware and software products over the lifetime of given programs which Luminar’s technology is integrated into or provided for, based primarily on contractual pricing terms and good faith estimates of “take rates” of Luminar’s technology on vehicles. Customer production vehicle volume estimates (and take rates when applicable) are largely sourced from (i) the OEM/customer, (ii) IHS Markit or other 3rd party estimates, and/or (iii) Luminar’s management good faith estimates. |
• | Level 0 – Active Safety: |
• | Luminar value-add: |
• | Levels 1 and 2 – Driver Assist head-on collision assistance which will require simultaneous braking and steering control. |
• | Luminar value-add: |
• | Levels 3 and 4 – Highway Autonomy: |
• | Luminar value-add: hands-off and eyes-off operation. This allows the driver to utilize their time for something other than supervising the driving function, which is the ultimate product purpose of autonomy. |
• | Levels 4 and 5 – Urban/Full Autonomy: |
• | Luminar value-add: |
• | Smart Cities. |
• | Aerospace and Defense. |
• | Smart Cities. |
• | Aerospace & Defense. off-road. While our products are used in many different applications, most involve enabling some form of autonomous drive capability. We anticipate entering into multi-year supply agreements with our defense contractor partners in this market to generate a significant number of sensor sales in the future. We also expect that most of our defense contractor partners will integrate our perception software into their solutions. |
• | maintain sensing superiority through advanced sensor development; |
• | provide actionable data through continual perception software refinement; and |
• | drive vehicle feature delivery through internal and external investment. |
• | Where is the road, how is it organized into lanes, and which is the proper lane? |
• | What driving rules apply to these lanes (e.g., lane change permission, speed, direction, traffic type)? |
• | How is the vehicle moving now (speed, direction)? |
• | What obstacles and other fellow travelers are in or near the roadway? |
• | Where are these external objects (which lane, sidewalk, etc.), and how are they moving? |
• | Automatic sensor discovery to expedite system startup time; |
• | Extrinsic calibration to automate multi-lidar geometrical alignment; |
• | Proprietary middleware to streamline advanced user interaction with both our hardware and software; |
• | Horizon tracking to automate region-of-interest |
• | Normal vector point attributes to associate common surfaces like drivable space quickly and accurately assess object headings without multiple frames; and |
• | Velocity vector point attribute to provide both radial and crossing velocities, point-by-point |
• | Semantic Segmentation |
• | Instance detection and Tracking |
• | State Estimation – |
• | Highway Autonomy: |
• | Proactive Safety: out-of-the-loop |
• | How we perform against and complement entrenched, non-lidar sensing technologies currently in-use; and |
• | How we perform against potential lidar competitors. |
• | Range |
• | Resolution |
• | Field-of-view |
• | Fidelity |
• | Frame rate. |
Design Area |
Common Lidar Architectures |
Luminar Lidar Architecture | ||
Wavelength |
905nm • Range limited by eye-safety • Resolution limited by eye-safety |
1550nm • Low cost with single pixel Ingas • Allows for long range, high resolution • Allows for deeper weather penetration | ||
Ranging |
FMCW • Range/Resolution limited by continuous wave measurement • Costly due to high transceiver count |
Single-pulse time of flight • Low complexity, low part-count • High rate measurements with high confidence | ||
Single Photon Detection • Range/Resolution limited by continuous wave measurement • Costly due to large, complex detector array |
Design Area |
Common Lidar Architectures |
Luminar Lidar Architecture | ||
Scanning |
Flash • Range limited by eye-safety • Costly due to large, complex detector array |
Low-mass, encoded mirror scanning• Scanning of an isolated, field of view • Low noise and rejection of uncontrolled light (sun, headlights, other lidar) | ||
Spinning 1D Array • Lifetime limited due to massive mechanical motor • Software reliability limited by noise and artifacts • Costly due to high alignment burden and component count |
||||
MEMS • Range/Resolution limited by high noise • Angular precision limited by fragile, non-micro scanner• Software reliability limited by noise and artifacts |
||||
Optical Phased Array • Range limited due to transmit loss • Resolution limited due to poor beam control and quality • Low reliability due to side-lobe illumination |
Name |
Age |
Position | ||
Executive Officers |
||||
Austin Russell |
25 | Chairperson, Director, President and Chief Executive Officer | ||
Thomas J. Fennimore |
45 | Chief Financial Officer | ||
M. Scott Faris |
55 | Chief Business Officer | ||
Jason Eichenholz |
49 | Chief Technology Officer | ||
Non-Employee Directors |
||||
Alec E. Gores (2) (3) |
67 | Director | ||
Matthew J. Simoncini (1) (2) |
60 | Director | ||
Scott A. McGregor (1) |
64 | Director | ||
Benjamin J. Kortlang (1) |
45 | Director |
(1) | Member of the audit committee. |
(2) | Member of the compensation committee. |
(3) | Member of the nominating and corporate governance committee. |
• | Class I, which consists of Scott McGregor and Benjamin Kortlang, whose terms will expire at our first annual meeting of stockholders to be held after consummation of the Business Combination; |
• | Class II, which consists of Alec E. Gores and Matthew J. Simoncini, whose terms will expire at our second annual meeting of stockholders to be held after consummation of the Business Combination; and |
• | Class III, which consists of Austin Russell, whose term will expire our third annual meeting of stockholders to be held after consummation of the Business Combination. |
• | selecting a qualified firm to serve as the independent registered public accounting firm to audit our financial statements; |
• | helping to ensure the independence and overseeing the performance of the independent registered public accounting firm; |
• | reviewing and discussing the results of the audit with the independent registered public accounting firm and reviewing, with management and that firm, our interim and year-end operating results; |
• | reviewing our financial statements and critical accounting policies and estimates; |
• | reviewing the adequacy and effectiveness of our internal controls; |
• | developing procedures for employees to submit concerns anonymously about questionable accounting, internal accounting controls, or audit matters; |
• | overseeing our policies on risk assessment and risk management; |
• | overseeing compliance with our code of business conduct and ethics; |
• | reviewing related party transactions; and |
• | approving or, as permitted, pre-approving all audit and all permissible non-audit services to be performed by the independent registered public accounting firm. |
• | reviewing, approving and determining, or making recommendations to the Board regarding, the compensation of our executive officers, including the Chief Executive Officer; |
• | making recommendations regarding non-employee director compensation to our full Board; |
• | administering our equity compensation plans and agreements with our executive officers; |
• | reviewing, approving and administering incentive compensation and equity compensation plans; and |
• | reviewing and approving our overall compensation philosophy. |
• | identifying, evaluating and selecting, or making recommendations to the Board regarding nominees for election to the Board and its committees; |
• | considering and making recommendations to the Board regarding the composition of the Board and its committees; |
• | developing and making recommendations to the Board regarding corporate governance guidelines and matters; |
• | overseeing our corporate governance practices; |
• | overseeing the evaluation and the performance of the Board and individual directors; and |
• | contributing to succession planning. |
• | for any transaction from which the director derives an improper personal benefit; |
• | for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |
• | for any unlawful payment of dividends or redemption of shares; or |
• | for any breach of a director’s duty of loyalty to the corporation or its stockholders. |
Name and Principal Position |
Fiscal Year |
Salary ($) |
All Other Compensation ($) |
Total ($) |
||||||||||||
Austin Russell President and Chief Executive Officer |
2019 | 175,000 | — | 175,000 | ||||||||||||
Scott Faris Chief Business Officer |
2019 | 300,000 | — | 300,000 | ||||||||||||
Jason Eichenholz Chief Technology Officer |
2019 | 200,000 | — | 200,000 |
Stock awards |
||||||||
Name |
Number of shares or units of stock that have not vested (#) |
Market value of shares or units of stock that have not vested ($) |
||||||
Austin Russell |
— | — | ||||||
Scott Faris |
11,250 | (1) |
255,713 | (2) | ||||
Jason Eichenholz |
— | — |
(1) | Represents Legacy Luminar restricted stock issued April 24, 2017, which was subject to release from Legacy Luminar’s repurchase right per the following schedule: 1/4 of the grant on September 1, 2017, and 1/48 of the total grant on each monthly anniversary thereafter until September 1, 2020, at which time the entire award became vested. |
(2) | Determined with reference to $22.73, the value of a share of Legacy Luminar Class A common stock on December 31, 2019. |
• | a transfer of all or substantially all of the Company’s assets; |
• | a merger, consolidation or other capital reorganization or business combination transaction of the Company with or into another corporation, entity or person; |
• | the consummation of a transaction in which any person becomes the beneficial owner, directly or indirectly, of at least 50% of our then outstanding capital stock; or |
• | a change in the effective control of the Company; |
• | a transfer of all or substantially all of the Company’s assets; |
• | a merger, consolidation or other capital reorganization or business combination transaction of the Company with or into another corporation, entity or person; |
• | the consummation of a transaction in which any person becomes the beneficial owner, directly or indirectly, of at least 50% of our then outstanding capital stock; or |
• | a change in the effective control of the Company; |
• | a transfer of all or substantially all of the Company’s assets; |
• | a merger, consolidation or other capital reorganization or business combination transaction of the Company with or into another corporation, entity or person; |
• | the consummation of a transaction in which any person becomes the beneficial owner, directly or indirectly, of at least 50% of our then outstanding capital stock; or |
• | a change in the effective control of the Company; |
• | we, Gores or Legacy Luminar have been or are to be a participant; |
• | the amounts involved exceeded or exceeds $120,000; and |
• | any of our directors, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. |
Name of Stockholder (1) |
SAFE Principal Amount ($) |
Shares of Series A-2 Preferred Stock |
Shares of Series A-7 Preferred Stock |
Shares of Series A-9 Preferred Stock |
||||||||||||
GVA Auto, LLC* |
20,000,000 | 1,322,780 | ||||||||||||||
Scott A. McGregor (2) |
1,000,000 | 25,658 |
* | Owners of more than 5% of Luminar capital stock. |
(1) | Additional details regarding these stockholders and their equity holdings are provided in this prospectus under the section “ Principal Securityholders |
(2) | Scott A. McGregor is a member of the Board. |
Name of Stockholder (1) |
No. of Shares (Series A) |
Aggregate Purchase Price ($) |
||||||
G2VP I, LLC for itself and as nominee for G2VP Founders Fund I, LLC* (2) |
461,852 | 19,999,992.83 |
* | Owners of more than 5% of Luminar capital stock. |
(1) | Additional details regarding these stockholders and their equity holdings are provided in this prospectus under the section “ Principal Securityholders |
(2) | G2VP I, LLC is an affiliate of Benjamin J. Kortlang, a member of the Board. |
Name of Stockholder (1) |
No. of Shares (Series A-2) |
Aggregate Purchase Price ($) |
||||||
GVA Auto, LLC* |
1,322,780 | 20,000,000 |
* | Owners of more than 5% of Luminar capital stock. |
(1) | Additional details regarding this stockholder and its equity holdings are provided in this prospectus under the section “ Principal Securityholders |
Name of Stockholder (1) |
No. of Shares (Series A-9) |
Aggregate Purchase Price ($) |
||||||
Scott A. McGregor (2) |
25,658 | 1,000,000 |
(1) | Additional details regarding this stockholder and his equity holdings are provided in this prospectus under the section “ Principal Securityholders |
(2) | Scott A. McGregor is a member of the Board. |
Name of Stockholder (1) |
No. of Shares (Series X) |
Aggregate Purchase Price ($) |
||||||
G2VP I, LLC for itself and as nominee for G2VP Founders Fund I, LLC* (2) |
6,839 | $ | 928,640.46 |
* | Owners of more than 5% of Luminar capital stock. |
(1) | Additional details regarding these stockholders and their equity holdings are provided in this prospectus under the section “ Principal Securityholders |
(2) | G2VP I, LLC is an affiliate of Benjamin J. Kortlang, a member of the Board. |
• | each person known by us to be the beneficial owner of more than 5% of our outstanding Common Stock; |
• | each of our executive officers and directors; and |
• | all executive officers and directors of the Company as a group. |
Name and Address of Beneficial Owners |
Number of Shares of Class A Stock |
% of Class A Stock |
Number of Shares of Class B Stock |
% of Class B Stock |
% of Common Stock |
% of Total Voting Power ** |
||||||||||||||||||
Five Percent Holders |
||||||||||||||||||||||||
G2VP I, LLC (for itself and as nominee for G2VP Founders Fund I, LLC) (1) |
15,947,553 | 7.3 | % | — | — | 4.9 | % | 1.3 | % | |||||||||||||||
GVA Auto, LLC (2) |
18,030,728 | 8.2 | % | — | — | 5.6 | % | 1.4 | % | |||||||||||||||
Current Directors and Named Executive Officers |
||||||||||||||||||||||||
Austin Russell |
— | — | 105,118,203 | 100.0 | % | 32.5 | % | 82.8 | % | |||||||||||||||
Thomas J. Fennimore |
— | — | — | — | — | — | ||||||||||||||||||
Alec E. Gores (3) |
10,943,499 | 5.0 | % | — | — | 3.4 | % | * | ||||||||||||||||
Jason Eichenholz |
4,034,770 | 1.8 | % | — | — | 1.3 | % | * | ||||||||||||||||
M. Scott Faris (4) |
1,039,359 | * | — | — | * | * | ||||||||||||||||||
Matthew J. Simoncini |
— | — | — | — | — | — | ||||||||||||||||||
Scott A. McGregor |
917,688 | * | * | * | ||||||||||||||||||||
Benjamin J. Kortlang (1) |
15,947,553 | 7.3 | % | — | — | 4.9 | % | 1.3 | % | |||||||||||||||
All Directors and Executive Officers as a Group (8 Individuals) |
32,865,830 | 15.0 | % | 105,118,203 | 100.0 | % | 10.1 | % | 85.4 | % |
* | Less than one percent. |
** | Percentage of total voting power represents voting power with respect to all shares of Class A Stock and Class B Stock, as a single class. Each share of Class B Stock is entitled to ten votes per share and each share of Class A Stock is entitled to one vote per share. For more information about the voting rights of Common Stock, see the section titled “ Description of Securities” |
(1) | Represents shares of Class A Stock held by G2VP I, LLC for itself and as nominee for G2VP Founders Fund I, LLC (“G2VP”). Benjamin J. Kortlang, a member of the Board, Brook Porter, Daniel Oros and David Mount are the Managing Members of G2VP I Associates, LLC, the Managing Member of G2VP, and therefore, may be deemed to hold voting and dispositive power over the shares held by G2VP. The address of G2VP is 2730 Sand Hill Road, Suite 210, Menlo Park, CA 94025. |
(2) | Represents shares of Class A Stock held by GVA Auto, LLC. Pavel Cherkashin is the Managing Partner of GVA Capital, which is the Manager of GVA Auto, LLC, and therefore, may be deemed to hold voting and dispositive power over the shares held by GVA Auto, LLC. The address of GVA Auto, LLC is 908 Broadway, San Francisco, CA 94133. |
(3) | Consists of (i) 8,932,500 shares of Class A Stock held by GM Sponsor LLC and (ii) 2,010,999 shares of Class A Stock held by AEG Holdings, LLC. AEG Holdings, LLC, is the managing member of GM Sponsor LLC and Alec E. Gores is the managing member of AEG Holdings, LLC. Voting and disposition decisions with respect to such securities are made by Mr. Gores. The address for AEG Holdings, LLC is 6260 Lookout Road, Boulder, CO 80301. |
(4) | Consists of (i) 817,856 shares of Class A Stock held by Mr. Faris and (ii) 221,503 shares of Class A Stock subject to Mr. Faris’ outstanding stock option, which is the portion of such option that is exercisable within 60 days of December 15, 2020. |
Shares of Class A Stock |
Warrants to Purchase Class A Stock |
|||||||||||||||||||||||||||||||
Name |
Number Beneficially Owned Prior to Offering |
Number Registered for Sale Hereby |
Number Beneficially Owned After Offering |
Percent Owned After Offering |
Number Beneficially Owned Prior to Offering |
Number Registered for Sale Hereby |
Number Beneficially Owned After Offering |
Percent Owned After Offering |
||||||||||||||||||||||||
Holders of Founder Shares |
||||||||||||||||||||||||||||||||
Randall Bort (1) |
25,000 | 25,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Michael Cramer (2) |
25,000 | 25,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Joseph Gatto (3) |
25,000 | 25,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
GM Sponsor LLC (4) (9) |
8,932,500 | 8,932,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
HRM Holdings LLC (5) (9) |
992,500 | 992,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Holder of Executive Shares |
||||||||||||||||||||||||||||||||
Austin Russell (6) |
105,118,203 | 115,573,337 | — | — | — | — | — | — | ||||||||||||||||||||||||
Holders of Private Warrants |
||||||||||||||||||||||||||||||||
GM Sponsor LLC (7) (9) |
3,333,333 | 3,333,333 | — | — | 3,333,333 | 3,333,333 | — | — | ||||||||||||||||||||||||
HRM Holdings LLC (8)(9) |
3,333,333 | 3,333,333 | — | — | 3,333,333 | 3,333,333 | — | — | ||||||||||||||||||||||||
Holders of Merger Consideration Shares |
||||||||||||||||||||||||||||||||
G2VP I, LLC (for itself and as nominee for G2VP Founders Fund I, LLC) (10) |
15,947,553 | 17,524,436 | — | — | — | — | — | — | ||||||||||||||||||||||||
GVA Auto, LLC (11) |
18,030,728 | 19,824,077 | — | — | — | — | — | — | ||||||||||||||||||||||||
AEG Holdings, LLC (4) (9) (12) |
2,010,999 | 2,010,999 | — | — | — | — | — | — | ||||||||||||||||||||||||
Affiliates of Luminar (Holders of Merger Consideration Shares and/or Rollover Options) |
||||||||||||||||||||||||||||||||
Alec E. Gores (4) (7) (9) (12) |
10,943,499 | 10,943,499 | — | — | — | — | — | — | ||||||||||||||||||||||||
Matthew J. Simoncini (13) |
340,773 | 340,773 | — | — | — | — | — | — | ||||||||||||||||||||||||
Scott A. McGregor (14) |
917,688 | 1,008,962 | — | — | — | — | — | — | ||||||||||||||||||||||||
Benjamin J. Kortlang (10) |
15,947,553 | 17,524,436 | — | — | — | — | — | — | ||||||||||||||||||||||||
Thomas J. Fennimore (15) |
1,840,176 | 1,840,176 | — | — | — | — | — | — | ||||||||||||||||||||||||
M. Scott Faris (16) |
1,635,712 | 1,717,056 | — | — | — | — | — | — | ||||||||||||||||||||||||
Jason Eichenholz (17) |
4,034,770 | 4,436,071 | — | — | — | — | — | — | ||||||||||||||||||||||||
Affiliates of Gores (Holders of Merger Consideration Shares) |
||||||||||||||||||||||||||||||||
J.P. Morgan Trust Company of Delaware (Trustee of the C. Dean Metropoulos 2015 Delaware Trust) (18) |
100,378 | 100,378 | — | — | — | — | — | — |
Shares of Class A Stock |
Warrants to Purchase Class A Stock |
|||||||||||||||||||||||||||||||
Name |
Number Beneficially Owned Prior to Offering |
Number Registered for Sale Hereby |
Number Beneficially Owned After Offering |
Percent Owned After Offering |
Number Beneficially Owned Prior to Offering |
Number Registered for Sale Hereby |
Number Beneficially Owned After Offering |
Percent Owned After Offering |
||||||||||||||||||||||||
J.P. Morgan Trust Company of Delaware (Trustee of the 2016 Evan D. Metropoulos Trust) (19) |
100,378 | 100,378 | — | — | — | — | — | — | ||||||||||||||||||||||||
J.P. Morgan Trust Company of Delaware (Trustee of the 2016 J. Daren Metropoulos Trust) (20) |
100,378 | 100,378 | — | — | — | — | — | — | ||||||||||||||||||||||||
Andrew McBride (21) |
4,143 | 4,143 | — | — | — | — | — | — |
(1) | Randall Bort is a former member of our Board who holds Founder Shares. The address for Mr. Bort is 9800 Wilshire Boulevard, Beverly Hills, CA 90212. |
(2) | Michael Cramer is a former member of our Board who holds Founder Shares. The address for Mr. Cramer is 9800 Wilshire Boulevard, Beverly Hills, CA 90212. |
(3) | Joseph Gatto is a former member of our Board who holds Founder Shares. Mr. Gatto is an affiliate of a broker-dealer. Mr. Gatto acquired the shares being registered hereunder in the ordinary course of business, and at the same time of the acquisition of the shares described herein, he did not have any arrangements or understandings with any person to distribute such securities. The address for Mr. Gatto is 9800 Wilshire Boulevard, Beverly Hills, CA 90212. |
(4) | Represents 8,932,500 Founders Shares held by GM Sponsor LLC (“GM”). AEG Holdings, LLC (“AEG”) is the managing member of GM and Alec E. Gores is the managing member of AEG. Voting and disposition decisions with respect to securities held by GM are made by Mr. Gores. Mr. Gores is a member of our Board. The address for GM is 9800 Wilshire Boulevard, Beverly Hills, CA 90212 and the address for AEG is 6260 Lookout Road, Boulder, CO 80301. |
(5) | Represents 992,500 Founders Shares held by HRM Holdings LLC. C. Dean Metropoulos is the managing member of HRM Holdings LLC (“HRM”) and various trusts for the benefit of Mr. Metropoulos and members of his immediate family are the members of HRM. Voting and disposition decisions with respect to securities held by HRM are made by Mr. Metropoulos. The address for HRM and Mr. Metropoulos is 200 Greenwich Avenue, Greenwich, CT 06830. |
(6) | Includes (i) solely with respect to the “Number Registered for Sale Hereby” column, 10,455,134 shares of Class A Stock issuable upon the conversion of the Class B Stock issuable as Earn-Out Shares and (ii) 105,118,204 shares of Class B Stock which are convertible into Class A Stock on a one-to-one basis as more fully described in the section titled “ Description of Securities” |
(7) | Represents 3,333,333 shares of Class A Stock issuable upon exercise of Private Warrants held by GM Sponsor, LLC. AEG Holdings, LLC is the managing member of GM Sponsor LLC and Alec E. Gores is the managing member of AEG Holdings, LLC. Voting and disposition decisions with respect to such securities are made by Mr. Gores. Mr. Gores disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein. Mr. Gores is a member of our Board. The address for AEG Holdings, LLC is 6260 Lookout Road, Boulder, CO 80301. |
(8) | Represents 3,333,333 shares of Class A Stock issuable upon exercise of Private Warrants held by HRM Holdings LLC. Dean Metropoulos is the managing member of HRM Holdings LLC. Voting and disposition decisions with respect to such securities are made by Mr. Metropoulos. Mr. Metropoulos disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein. The address for HRM Holdings, LLC is 200 Greenwich Avenue, Greenwich, CT, 06830. |
(9) | Because of the relationship among AEG, GM, HRM and Sponsor, Mr. Gores and Mr. Metropoulos may be deemed to beneficially own these securities to the extent of their respective pecuniary interests. Mr. Gores and Mr. Metropoulos disclaim beneficial ownership of these securities except to the extent of their respective pecuniary interest therein, if any. |
(10) | Represents (i) 15,947,553 shares of Class A Stock held by G2VP I, LLC for itself and as nominee for G2VP Founders Fund I, LLC (“G2VP”) and (ii) solely with respect to the “Number Registered for Sale Hereby” column, 1,576,883 shares of Class A Stock issuable as Earn-Out Shares. Benjamin J. Kortlang, a member of our Board, Brook Porter, Daniel Oros and David Mount are the Managing Members of G2VP I Associates, LLC, the Managing Member of G2VP, and therefore, may be deemed to hold voting and dispositive power over the shares held by G2VP. The address of G2VP is 3280 Alpine Road, Portola Valley, CA 94028. |
(11) | Represents (i) 18,030,728 shares of Class A Stock held by GVA Auto, LLC and (ii) solely with respect to the “Number Registered for Sale Hereby” column, 1,793,349 shares of Class A Stock issuable as Earn-Out Shares. Pavel Cherkashin is the Managing Partner of GVA Capital, which is the Manager of GVA Auto, LLC, and therefore, may be deemed to hold voting and dispositive power over the shares held by GVA Auto, LLC. The address of GVA Auto, LLC is 908 Broadway, San Francisco, CA 94133. |
(12) | Represents 2,010,999 shares of Class A Stock held by AEG Holdings, LLC. Alec E. Gores is the managing member of AEG Holdings, LLC. Voting and disposition decisions with respect to such securities are made by Mr. Gores. |
(13) | Represents 340,773 shares of Class A Stock issuable upon exercise of outstanding Rollover Options. |
(14) | Represents (i) 917,688 shares of Class A Stock and (ii) solely with respect to the “Number Registered for Sale Hereby” column, 91,274 shares of Class A Stock issuable as Earn-Out Shares. |
(15) | Represents 1,840,176 shares of Class A Stock issuable upon exercise of outstanding Rollover Options. |
(16) | Represents (i) 817,856 shares of Class A Stock, (ii) 817,856 shares of Class A Stock issuable upon exercise of outstanding Rollover Options, and (iii) solely with respect to the “Number Registered for Sale Hereby” column, 81,344 shares of Class A Stock issuable as Earn-Out Shares. |
(17) | Represents (i) 4,034,770 shares of Class A Stock and (ii) solely with respect to the “Number Registered for Sale Hereby” column, 401,301 shares of Class A Stock issuable as Earn-Out Shares. |
(18) | J.P. Morgan Trust Company of Delaware is the trustee of the C. Dean Metropoulos 2015 Delaware Trust (the “2015 CDM Trust”) and is therefore deemed to hold voting and dispositive powers over the securities held by the 2015 CDM Trust. The address for 2015 CDM Trust is 500 Stanton Christiana Road, Newark, DE 19713. |
(19) | J.P. Morgan Trust Company of Delaware is the trustee of the 2016 Evan D. Metropoulos Trust (the “2016 EDM Trust”) and is therefore deemed to hold voting and dispositive powers over the securities held by the 2016 EDM Trust. The address for 2016 EDM Trust is 500 Stanton Christiana Road, Newark, DE 19713. |
(20) | J.P. Morgan Trust Company of Delaware is the trustee of the 2016 J. Daren Metropoulos Trust (the “2016 JDM Trust”) and is therefore deemed to hold voting and dispositive powers over the securities held by the 2016 JDM Trust. The address for 2016 JDM Trust is 500 Stanton Christiana Road, Newark, DE 19713. |
(21) | Andrew McBride is our former Chief Financial Officer. The address for Mr. McBride is 9800 Wilshire Boulevard, Beverly Hills, CA 90212. |
• | 715,000,000 shares of Class A Stock, $0.0001 par value per share; |
• | 121,000,000 shares of Class B Stock, $0.0001 par value per share; |
• | 0 shares of Class F Common Stock, $0.0001 par value per share (“Class F Stock”); and |
• | 10,000,000 shares of undesignated Preferred Stock, $0.0001 par value per share (“Preferred Stock”). |
• | if we were to seek to amend the Second Amended and Restated Certificate of Incorporation to increase or decrease the par value of a class of the capital stock, then that class would be required to vote separately to approve the proposed amendment; and |
• | if we were to seek to amend the Second Amended and Restated Certificate of Incorporation in a manner that alters or changes the powers, preferences, or special rights of a class of capital stock in a manner that affected its holders adversely, then that class would be required to vote separately to approve the proposed amendment. |
• | in whole and not in part; |
• | at a price of $0.01 per Public Warrant; |
• | upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and |
• | if, and only if, the reported last sale price of the Class A Stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending three business days before we send the notice of redemption to the warrant holders. |
• | in whole and not in part; |
• | at a price equal to a number of shares of Class A Stock to be determined by reference to the table below, based on the redemption date and the “fair market value” of our Class A Stock except as otherwise described below; |
• | upon a minimum of 30 days’ prior written notice of redemption; and |
• | if, and only if, the last reported sale price of our Class A Stock equals or exceeds $10.00 per share (as adjusted per share splits, share dividends, reorganizations, reclassifications, recapitalizations and the like) on the trading day prior to the date on which we send the notice of redemption to the warrant holders. |
Redemption Date |
Fair Market Value of Class A Stock |
|||||||||||||||||||||||||||||||||||
(period to expiration of warrants) |
$10.00 |
$11.00 |
$12.00 |
$13.00 |
$14.00 |
$15.00 |
$16.00 |
$17.00 |
$18.00 |
|||||||||||||||||||||||||||
57 months |
0.257 | 0.277 | 0.294 | 0.310 | 0.324 | 0.337 | 0.348 | 0.358 | 0.365 | |||||||||||||||||||||||||||
54 months |
0.252 | 0.272 | 0.291 | 0.307 | 0.322 | 0.335 | 0.347 | 0.357 | 0.365 | |||||||||||||||||||||||||||
51 months |
0.246 | 0.268 | 0.287 | 0.304 | 0.320 | 0.333 | 0.346 | 0.357 | 0.365 | |||||||||||||||||||||||||||
48 months |
0.241 | 0.263 | 0.283 | 0.301 | 0.317 | 0.332 | 0.344 | 0.356 | 0.365 | |||||||||||||||||||||||||||
45 months |
0.235 | 0.258 | 0.279 | 0.298 | 0.315 | 0.330 | 0.343 | 0.356 | 0.365 | |||||||||||||||||||||||||||
42 months |
0.228 | 0.252 | 0.274 | 0.294 | 0.312 | 0.328 | 0.342 | 0.355 | 0.364 | |||||||||||||||||||||||||||
39 months |
0.221 | 0.246 | 0.269 | 0.290 | 0.309 | 0.325 | 0.340 | 0.354 | 0.364 | |||||||||||||||||||||||||||
36 months |
0.213 | 0.239 | 0.263 | 0.285 | 0.305 | 0.323 | 0.339 | 0.353 | 0.364 | |||||||||||||||||||||||||||
33 months |
0.205 | 0.232 | 0.257 | 0.280 | 0.301 | 0.320 | 0.337 | 0.352 | 0.364 | |||||||||||||||||||||||||||
30 months |
0.196 | 0.224 | 0.250 | 0.274 | 0.297 | 0.316 | 0.335 | 0.351 | 0.364 | |||||||||||||||||||||||||||
27 months |
0.185 | 0.214 | 0.242 | 0.268 | 0.291 | 0.313 | 0.332 | 0.350 | 0.364 | |||||||||||||||||||||||||||
24 months |
0.173 | 0.204 | 0.233 | 0.260 | 0.285 | 0.308 | 0.329 | 0.348 | 0.364 | |||||||||||||||||||||||||||
21 months |
0.161 | 0.193 | 0.223 | 0.252 | 0.279 | 0.304 | 0.326 | 0.347 | 0.364 | |||||||||||||||||||||||||||
18 months |
0.146 | 0.179 | 0.211 | 0.242 | 0.271 | 0.298 | 0.322 | 0.345 | 0.363 | |||||||||||||||||||||||||||
15 months |
0.130 | 0.164 | 0.197 | 0.230 | 0.262 | 0.291 | 0.317 | 0.342 | 0.363 | |||||||||||||||||||||||||||
12 months |
0.111 | 0.146 | 0.181 | 0.216 | 0.250 | 0.282 | 0.312 | 0.339 | 0.363 | |||||||||||||||||||||||||||
9 months |
0.090 | 0.125 | 0.162 | 0.199 | 0.237 | 0.272 | 0.305 | 0.336 | 0.362 | |||||||||||||||||||||||||||
6 months |
0.065 | 0.099 | 0.137 | 0.178 | 0.219 | 0.259 | 0.296 | 0.331 | 0.362 | |||||||||||||||||||||||||||
3 months |
0.034 | 0.065 | 0.104 | 0.150 | 0.197 | 0.243 | 0.286 | 0.326 | 0.361 | |||||||||||||||||||||||||||
0 months |
— | — | 0.042 | 0.115 | 0.179 | 0.233 | 0.281 | 0.323 | 0.361 |
• | prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted |
• | the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding |
• | at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder. |
• | Dual Class Common Stock |
• | Board of Directors Vacancies |
• | Classified Board Management |
• | Directors Removed Only for Cause |
• | Supermajority Requirements for Amendments of The Second Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws two-thirds of the voting power of all of the then-outstanding shares of voting stock will be required to amend certain provisions of the Second Amended and Restated Certificate of Incorporation, including provisions relating to the classified Board, the size of the Board, removal of directors, special meetings, actions by written consent, and designation of Preferred Stock. In addition, the affirmative vote of holders of 75% of the voting power of each of the then-outstanding Class A Stock and Class B Stock, voting separately by class, is required to amend the provisions of the Second Amended and Restated Certificate of Incorporation relating to the terms of the Class B Stock. The affirmative vote of holders of at least two-thirds of the voting power of all of the then-outstanding shares of voting stock is required to amend or repeal the Amended and Restated Bylaws, although the Amended and Restated Bylaws may be amended by a simple majority vote of the Board. |
• | Stockholder Action; Special Meeting of Stockholders |
called only by a majority of the Whole Board, the chairman of the Board, or the chief executive officer, thus prohibiting a stockholder from calling a special meeting. The Second Amended and Restated Certificate of Incorporation provides that the stockholders may not take action by written consent, but may only take action at annual or special meetings of stockholders. As a result, holders of capital stock are not able to amend the Amended and Restated Bylaws or remove directors without holding a meeting of stockholders called in accordance with the Amended and Restated Bylaws. These provisions might delay the ability of stockholders to force consideration of a proposal or for stockholders to take any action, including the removal of directors. |
• | Notice Requirements for Stockholder Proposals and Director Nominations |
• | No Cumulative Voting |
• | Issuance of Undesignated Preferred Stock |
• | Choice of Forum |
the threat of inconsistent or contrary rulings by different courts, among other considerations, the Second Amended and Restated Certificate of Incorporation provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. |
• | the issuer of the securities that was formerly a shell company has ceased to be a shell company; |
• | the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act; |
• | the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and |
• | at least one year has elapsed from the time that the issuer filed current Form 10-type information with the SEC reflecting its status as an entity that is not a shell company. |
• | 1% of the total number of shares of the Class A Stock then outstanding; or |
• | the average weekly reported trading volume of the Class A Stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. |
• | any breach of the director’s duty of loyalty to the Company or to its stockholders; |
• | acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; |
• | unlawful payment of dividends or unlawful stock repurchases or redemptions; and |
• | any transaction from which the director derived an improper personal benefit. |
• | purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; |
• | ordinary brokerage transactions and transactions in which the broker solicits purchasers; |
• | block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; |
• | an over-the-counter |
• | through trading plans entered into by a Selling Securityholder pursuant to Rule 10b5-1 under the Exchange Act that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans; |
• | short sales; |
• | distribution to employees, members, limited partners or stockholders of the Selling Securityholders; |
• | through the writing or settlement of options or other hedging transaction, whether through an options exchange or otherwise |
• | by pledge to secured debts and other obligations; |
• | delayed delivery arrangements; |
• | to or through underwriters or agents; |
• | in “at the market” offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents; |
• | in privately negotiated transactions; |
• | in options transactions; and |
• | through a combination of any of the above methods of sale, as described below, or any other method permitted pursuant to applicable law. |
• | an individual who is a United States citizen or resident of the United States; |
• | a corporation or other entity treated as a corporation for United States federal income tax purposes created in, or organized under the law of, the United States or any state or political subdivision thereof; |
• | an estate the income of which is includible in gross income for United States federal income tax purposes regardless of its source; or |
• | a trust (A) the administration of which is subject to the primary supervision of a United States court and which has one or more United States persons (within the meaning of the Code) who have the authority to control all substantial decisions of the trust or (B) that has in effect a valid election under applicable Treasury regulations to be treated as a United States person. |
• | the gain is effectively connected with the conduct of a trade or business by the non-U.S. Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the non-U.S. Holder); |
• | the non-U.S. Holder is an individual who is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are met; or |
• | we are or have been a “United States real property holding corporation” for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the non-U.S. Holder held our Class A Stock or Warrants and, in the case where shares of our Class A Stock are regularly traded on an established securities market, the non-U.S. Holder has owned, directly or constructively, more than 5% of our Class A Stock at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. holder’s holding period for the shares of our Class A Stock. There can be no assurance that our Class A Stock will be treated as regularly traded on an established securities market for this purpose. |
Luminar Unaudited Condensed Financial Statements |
||||
F-2 | ||||
F-3 | ||||
F-4 | ||||
F-5 | ||||
F-7 | ||||
F-8 | ||||
Luminar Technologies, Inc.—Audited Financial Statements |
||||
F-34 | ||||
F-35 | ||||
F-36 | ||||
F-37 | ||||
F-39 | ||||
F-40 | ||||
Gores Metropoulos, Inc. Unaudited Financial Statements |
||||
F-75 | ||||
F-76 | ||||
F-77 | ||||
F-78 | ||||
F-79 | ||||
Gores Metropoulos, Inc. Audited Financial Statements |
||||
F-90 | ||||
F-91 | ||||
F-91 | ||||
F-92 | ||||
F-93 | ||||
F-94 | ||||
F-95 |
September 30, 2020 |
December 31, 2019 |
|||||||
(Unaudited) |
||||||||
Assets |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Restricted cash and cash equivalents |
||||||||
Marketable securities |
||||||||
Accounts receivable |
||||||||
Inventories |
||||||||
Other current assets |
||||||||
|
|
|
|
|||||
Total current assets |
||||||||
|
|
|
|
|||||
Property and equipment, net |
||||||||
Goodwill |
||||||||
Other long-term assets |
||||||||
|
|
|
|
|||||
Total assets |
$ | $ | ||||||
|
|
|
|
|||||
Liabilities, mezzanine equity and stockholders’ deficit |
||||||||
Accounts payable |
||||||||
Accrued liabilities |
||||||||
Current portion of long-term debt, net |
||||||||
Other current liabilities |
||||||||
|
|
|
|
|||||
Total current liabilities |
||||||||
|
|
|
|
|||||
Long-term debt, net |
||||||||
Warrant liabilities |
||||||||
Other long-term liabilities |
||||||||
|
|
|
|
|||||
Total liabilities |
$ | $ | ||||||
|
|
|
|
|||||
Commitments and contingencies (Note 15) |
||||||||
Mezzanine equity |
||||||||
Series A preferred stock, $ |
||||||||
Series X preferred stock, $ |
— | |||||||
Stockholders’ deficit |
||||||||
Founders’ preferred stock, $ |
||||||||
Class A common stock, $ |
||||||||
Class B common stock, $ |
||||||||
Additional paid-in capital |
||||||||
Accumulated other comprehensive loss |
( |
) | ( |
) | ||||
Treasury stock, at cost, |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total stockholders’ deficit |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total liabilities, mezzanine equity and stockholders’ deficit |
$ | $ | ||||||
|
|
|
|
Nine Month ended September 30, |
||||||||
2020 |
2019 |
|||||||
Net sales |
$ | $ | ||||||
Cost of sales |
||||||||
|
|
|
|
|||||
Gross loss |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Selling and marketing expenses |
||||||||
General and administrative expenses |
||||||||
Research and development expenses |
||||||||
|
|
|
|
|||||
Operating loss |
( |
) | ( |
) | ||||
Interest income |
||||||||
Interest expense |
( |
) | ( |
) | ||||
Change in fair value of SAFE notes |
— | ( |
) | |||||
Change in fair values of warrant liabilities |
( |
) | ( |
) | ||||
Loss on extinguishment of debt |
( |
) | ( |
) | ||||
Other income |
||||||||
Other expense |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Loss before income taxes |
( |
) | ( |
) | ||||
Income taxes |
||||||||
|
|
|
|
|||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
|||||
Net loss attributable to common stockholders, basic and diluted |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
|||||
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted |
||||||||
|
|
|
|
Nine Month ended September 30, |
||||||||
2020 |
2019 |
|||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Other comprehensive loss, net of tax: |
||||||||
Changes in unrealized loss on marketable securities |
( |
) | — | |||||
|
|
|
|
|||||
Comprehensive loss |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
Series A Convertible Preferred stock |
Founders Preferred Stock |
Common Stock |
Treasury stock |
Additional paid-in capital |
Accumulated other comprehensive (loss) |
Accumulated deficit |
Total stockholders’ deficit |
|||||||||||||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
Shares |
Amount |
Amount |
||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2018 |
— | $ | — | $ | — | $ | — | $ | $ | $ | — | $ | ( |
) | $ | ( |
) | |||||||||||||||||||||||||||
Issuance of restricted common stock |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Share-based compensation |
— | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
Repurchase of common stock (1) |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
Conversion of SAFE into preferred stock for cash, net of issuance costs of $ |
— | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
Conversion of SAFE into common stock |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Net loss |
— | — | — | — | — | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||||||||||||||
Conversion of debt into preferred stock |
— | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
Issuance of Series A stock for cash, net of issuance costs of $ |
— | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
Balance as of September 30, 2019 |
$ | $ | — | $ | — | $ | — | $ | $ | — | $ | ( |
) | $ | ( |
) | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) | Amounts within common stock and treasury stock round to zero. |
Series A Convertible Preferred stock |
Series X Convertible Preferred stock |
Founders Preferred Stock |
Common Stock |
Treasury stock |
Additional paid-in capital |
Accumulated other comprehensive (loss) |
Accumulated deficit |
Total stockholders’ deficit |
||||||||||||||||||||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
Shares |
Amount |
Shares |
Amount |
Amount |
||||||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2019 |
$ | — | — | — | $ | — | $ | — | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||||||||||||||||||||||||||||||||
Issuance of Series X stock for cash, net of issuance costs of $ |
— | — | $ | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
Repurchase of common stock (1) |
— | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
Issuance of restricted common stock |
— | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
Share-based compensation and Conversion to Common Stock |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Other comprehensive loss, net of tax |
— | — | — | — | — | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||||||||||||||
Net loss |
— | — | — | — | — | — | — | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
Balance as of September 30, 2020 |
$ | $ | $ | — | $ | — | $ | — | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||||||||||||||||||||||||||||||||
(1) | Amounts within common stock and treasury stock round to zero. |
Nine month ended September 30, |
||||||||
2020 |
2019 |
|||||||
Cash flows from operating activities: |
||||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
Depreciation and amortization |
||||||||
Change in fair value of warrants and SAFE liabilities |
||||||||
Write-down of inventories |
||||||||
Loss on disposal of property and equipment |
||||||||
Loss on extinguishment of debt |
||||||||
Share-based compensation |
||||||||
Loss on write off of property and equipment |
— | |||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
( |
) | ||||||
Inventories |
( |
) | ( |
) | ||||
Other current assets |
( |
) | ( |
) | ||||
Other long-term assets |
( |
) | ||||||
Accounts payable |
( |
) | ||||||
Accrued liabilities |
||||||||
Other current liabilities |
||||||||
Other long-term liabilities |
( |
) | ( |
) | ||||
Net cash used in operating activities |
( |
) | ( |
) | ||||
Cash flows from investing activities: |
||||||||
Purchase of marketable securities |
( |
) | — | |||||
Proceeds from maturities of marketable securities |
— | |||||||
Proceeds from sale of marketable securities |
— | |||||||
Purchase of property and equipment |
( |
) | ( |
) | ||||
Proceeds from disposal of property and equipment |
||||||||
Net cash used in investing activities |
( |
) | ( |
) | ||||
Cash flows from financing activities: |
||||||||
Settlement of SAFE notes |
— | ( |
) | |||||
Principal payments on financing obligations |
( |
) | ( |
) | ||||
Proceeds from the issuance of debt |
— | |||||||
Proceeds from issuance of SAFE notes |
— | |||||||
Principal payments on capital leases |
( |
) | ( |
) | ||||
Proceeds from issuance of Series A Convertible Preferred stock |
— | |||||||
Proceeds from issuance of Series X Convertible Preferred stock |
— | |||||||
Proceeds from issuance of restricted common stock |
— | |||||||
Financing costs paid for debt |
( |
) | ( |
) | ||||
Issuance cost paid for Series X Preferred stock |
( |
) | — | |||||
Payment made for merger related expense |
( |
) | — | |||||
Repurchase of Common Stock |
( |
) | ( |
) | ||||
Net cash provided by financing activities |
||||||||
Net increase in cash and cash equivalents and restricted cash and cash equivalents |
||||||||
Beginning cash and cash equivalents and restricted cash and cash equivalents |
||||||||
Ending cash and cash equivalents and restricted cash and cash equivalents |
||||||||
Supplemental disclosures of cash flow information: |
||||||||
Cash paid for interest |
$ | $ | ||||||
Supplemental disclosures of noncash investing and financing activities |
||||||||
Conversion of Bridge Note to Series A Convertible Preferred stock |
— | |||||||
Conversion of SAFE notes into common stock |
— | |||||||
Conversion of SAFE notes into Series A Convertible Preferred stock |
— | |||||||
Assets acquired on capital leases |
||||||||
Purchases of property and equipment recorded in accounts payable and accrued liabilities |
||||||||
Merger related expense recorded in accounts payable and accrued liabilities |
— | |||||||
Issuance cost for Series X preferred stock recorded in accounts payable |
— |
Nine months ended September 30, |
||||||||||||||||
2020 |
2019 |
|||||||||||||||
Revenue |
% of Revenue |
Revenue |
% of Revenue |
|||||||||||||
Revenue by primary geographical market: |
||||||||||||||||
North America |
$ | % | $ | % | ||||||||||||
Asia Pacific |
% | % | ||||||||||||||
Europe, Middle East, and Asia |
% | % | ||||||||||||||
Total |
$ | % | $ | % | ||||||||||||
Revenue by timing of recognition: |
||||||||||||||||
Revenue recognized at a point in time |
$ | % | $ | % | ||||||||||||
Revenue recognized over time |
% | % | ||||||||||||||
Total |
$ | % | $ | % | ||||||||||||
Revenue by segment |
||||||||||||||||
Autonomy Solutions |
$ | % | $ | % | ||||||||||||
Other Component Sales |
% | % | ||||||||||||||
Total |
$ | % | $ | % | ||||||||||||
As of |
||||||||
September 30, 2020 |
December 31, 2019 |
|||||||
Contract liabilities, current |
$ | $ | ||||||
Contract liabilities, non-current |
||||||||
Total contract liabilities |
$ | $ | ||||||
As of September 30, |
||||||||
2020 |
2019 |
|||||||
Beginning balance |
$ | $ | ||||||
Revenue recognized that was included in the contract liabilities beginning balance |
( |
) | ||||||
Increase due to cash received and not recognized as revenue and billings in excess of revenue recognized during the period |
||||||||
Ending balance |
$ | $ | ||||||
As of |
||||||||
September 30, 2020 |
December 31, 2019 |
|||||||
Raw materials |
$ | $ | ||||||
Work-in-process |
||||||||
Finished goods |
||||||||
Total inventory, net of allowance |
$ | $ | ||||||
Autonomy Solutions |
Other Component Sales |
Total |
||||||||||
Balance as of December 31, 2019 |
$ | $ | $ | |||||||||
Balance as of September 30, 2020 |
$ | $ | $ |
As of |
||||||||
September 30, 2020 |
December 31, 2019 |
|||||||
2017 Notes Principal Outstanding |
$ | — | $ | |||||
Unamortized discount (2017 Notes) |
— | ( |
) | |||||
2018 Notes |
— | |||||||
Unamortized discount (2018 Notes) |
— | ( |
) | |||||
New Notes |
— | |||||||
Unamortized discount (New Notes) |
( |
) | — | |||||
Net carrying amount |
||||||||
Less: current portion |
||||||||
Non-current portion |
$ | $ | ||||||
As of December 31, 2019 |
||||
Notes Principal outstanding |
$ | |||
Unamortized discount |
( |
) | ||
Net carrying amount |
||||
Less: current portion |
||||
Non-current portion |
$ | |||
As of |
||||||||
September 30, 2020 |
December 31, 2019 |
|||||||
Vehicle Loan |
$ | $ | ||||||
Additional Equipment Loan |
||||||||
Total |
||||||||
Less: current portion |
||||||||
Non-current portion |
$ | $ | ||||||
As of |
||||||||
September 30, 2020 |
December 31, 2019 |
|||||||
2017 Warrant |
$ | $ | ||||||
2018 Warrant |
||||||||
2020 Warrants |
||||||||
Total |
$ | $ | ||||||
As of September 30, 2020 |
As of December 31, 2019 |
|||||||||||||||||||||||
Shares Authorized |
Shares Issued and Outstanding |
Per share Liquidation Preference |
Shares Authorized |
Shares Issued and Outstanding |
Per share Liquidation Preference |
|||||||||||||||||||
Series A |
$ | $ | ||||||||||||||||||||||
Series A-1 |
||||||||||||||||||||||||
Series A-2 |
||||||||||||||||||||||||
Series A-3 |
||||||||||||||||||||||||
Series A-4 |
||||||||||||||||||||||||
Series A-5 |
||||||||||||||||||||||||
Series A-6 |
||||||||||||||||||||||||
Series A-7 |
||||||||||||||||||||||||
Series A-8 |
||||||||||||||||||||||||
Series A-9 |
||||||||||||||||||||||||
Series A-10 |
||||||||||||||||||||||||
Series A-11 |
||||||||||||||||||||||||
Series X |
— | — | — |
Effective Conversion Price |
||||
Series A |
$ | |||
Series A-1 |
||||
Series A-2 |
||||
Series A-3 |
||||
Series A-4 |
||||
Series A-5 |
||||
Series A-6 |
||||
Series A-7 |
||||
Series A-8 |
||||
Series A-9 |
||||
Series A-10 |
||||
Series A-11 |
||||
Series X |
Commitment Date |
Series |
Type of Consideration received (cash or settlement of other instruments) |
Effective Conversion Price |
Fair value of the Common Stock |
Number of Shares Issuable upon Conversion |
BCF |
||||||||||||||||
6/24/2019 |
A | $ | $ | $ | — | |||||||||||||||||
6/24/2019 |
A | — | ||||||||||||||||||||
6/24/2019 |
A-1 |
|||||||||||||||||||||
6/24/2019 |
A-2 |
|||||||||||||||||||||
6/24/2019 |
A-3 |
|||||||||||||||||||||
6/24/2019 |
A-4 |
— | ||||||||||||||||||||
6/24/2019 |
A-5 |
— | ||||||||||||||||||||
6/24/2019 |
A-6 |
— | ||||||||||||||||||||
6/24/2019 |
A-7 |
— | ||||||||||||||||||||
6/24/2019 |
A-8 |
— | ||||||||||||||||||||
6/24/2019 |
A-9 |
— | ||||||||||||||||||||
6/24/2019 |
A-10 |
— | ||||||||||||||||||||
6/24/2019 |
A-11 |
— | ||||||||||||||||||||
6/26/2019 |
A | — | ||||||||||||||||||||
7/15/2019 |
A | — | ||||||||||||||||||||
8/24/2020 to 9/22/2020 |
X | |||||||||||||||||||||
Total | $ | |||||||||||||||||||||
Fair Value Measured as of September 30, 2020 |
||||||||||||||||
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||
Assets: |
||||||||||||||||
Commercial papers |
$ | — | $ | $ | — | $ | ||||||||||
Corporate debt securities |
— | — | ||||||||||||||
Treasury bills |
— | — | ||||||||||||||
Agency securities |
— | — | ||||||||||||||
Asset backed securities |
— | |||||||||||||||
Foreign corporate debt |
— | |||||||||||||||
Total fair value |
$ | $ | $ | $ | ||||||||||||
Liabilities: |
||||||||||||||||
2017 Warrant |
$ | — | $ | — | $ | $ | ||||||||||
2018 Warrant |
— | — | ||||||||||||||
2020 Warrants |
— | — | ||||||||||||||
Total fair value |
$ | — | $ | — | $ | $ | ||||||||||
Fair Value Measured (in thousands) as of December 31, 2019 Using: |
||||||||||||||||
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||
Assets: |
||||||||||||||||
Commercial papers |
$ | — | $ | — | $ | |||||||||||
Corporate debt |
— | — | ||||||||||||||
Treasury bills |
— | — | ||||||||||||||
Total fair value |
$ | $ | $ | — | $ | |||||||||||
Liabilities: |
||||||||||||||||
2017 Warrant |
$ | — | $ | — | $ | $ | ||||||||||
2018 Warrant |
— | — | ||||||||||||||
Total fair value |
$ | — | $ | — | $ | $ | ||||||||||
For the nine months ended September 30, 2020 |
||||||||||||
2017 Warrant |
2018 Warrant |
2020 Warrants |
||||||||||
Balance-beginning of period |
$ | $ | $ | |||||||||
Additions |
— | — | ||||||||||
Exercise or conversion |
— | — | — | |||||||||
Measurement adjustments |
||||||||||||
Balance-end of period |
$ | $ | $ | |||||||||
For the nine months ended September 30, 2019 |
||||||||||||
SAFEs |
2017 Warrants |
2018 Warrants |
||||||||||
Balance-beginning of period |
$ | $ | $ | |||||||||
Additions |
— | — | ||||||||||
Exercise or conversion |
( |
) | — | — | ||||||||
Measurement adjustments |
||||||||||||
Balance-end of the nine months period |
$ | $ | $ | |||||||||
Nine Months ended September 30, |
||||||||
2020 |
2019 |
|||||||
Numerator: |
||||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Deemed dividend attributable to BCF |
( |
) | ( |
) | ||||
Net loss attributable to common shareholders |
$ | ( |
) | $ | ( |
) | ||
Denominator: |
||||||||
Weighted average Common shares outstanding- Basic |
||||||||
Dilutive effect of potential common shares |
— | — | ||||||
Weighted average Common shares outstanding- Diluted |
||||||||
Net loss per shares attributable to Common shareholders-Basic and Diluted |
$ | ( |
) | $ | ( |
) | ||
Nine Months ended September 30, |
||||||||
2020 |
2019 |
|||||||
Warrants |
||||||||
Stock options |
||||||||
Restricted Stock |
||||||||
Series A Convertible Preferred Stock |
||||||||
Series X Convertible Preferred Stock |
||||||||
Founders Preferred Stock |
||||||||
Total |
||||||||
9/30/2020 |
12/31/2019 |
|||||||
Expected term (years) (1) |
||||||||
Common stock (price per share) |
$ | $ | ||||||
Expected volatility (2) |
||||||||
Risk-free interest rate (3) |
||||||||
Dividend yield (4) |
(1) | The expected term is the length of time the grant is expected to be outstanding before it is exercised or terminated. This number is calculated as the midpoint between the vesting term and the original contractual term (contractual period to exercise). If the option contains graded vesting, then the vesting term would be based on the vesting pattern. |
(2) | Volatility, or the standard deviation of annualized returns, was calculated based on comparable companies’ report volatilities. |
(3) | Risk free rate was obtained from US treasury notes for the expected terms noted as of the valuation date. |
(4) | The Company has assumed a dividend yield of zero as they have no plans to declare dividends in the foreseeable future. |
Number of Common Stock options |
Weighted- Average Exercise Price |
Weighted- Average Remaining Contractual Life (Years) |
Aggregate Intrinsic Value (In Thousands) |
|||||||||||||
Outstanding as of December 31, 2019 |
$ | $ | ||||||||||||||
Granted |
— | — | ||||||||||||||
Exercised |
— | — | — | |||||||||||||
Forfeited |
( |
) | — | — | ||||||||||||
Expired |
— | — | — | — | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Outstanding as of September 30, 2020 |
$ | $ | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Vested and exercisable as of September 30, 2020 |
$ | $ | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Vested and expected to vest as of September 30, 2020 |
$ | $ | ||||||||||||||
|
|
|
|
|
|
|
|
Shares |
Weighted Average Grant Date Fair Value per Share |
|||||||
Outstanding as of December 31, 2019 |
$ | |||||||
Granted |
— | — | ||||||
Forfeited |
( |
) | ||||||
Vested |
( |
) | ||||||
|
|
|
|
|||||
Outstanding as of September 30, 2020 |
$ | |||||||
|
|
|
|
Shares |
Weighted Average Grant Date Fair Value per Share |
|||||||
Outstanding as of December 31, 2019 |
$ | |||||||
Granted |
— | — | ||||||
Exercised |
— | — | ||||||
Forfeited |
— | — | ||||||
Vested |
( |
) | ||||||
|
|
|
|
|||||
Outstanding as of September 30, 2020 |
$ | |||||||
|
|
|
|
Nine Months ended September 30, |
||||||||
2020 |
2019 |
|||||||
Cost of sales |
$ | $ | ||||||
Research and development |
||||||||
Sales and marketing |
||||||||
General and administrative |
||||||||
|
|
|
|
|||||
Total |
$ | $ | ||||||
|
|
|
|
Capital Leases |
Operating Leases |
|||||||
2020 |
$ | $ | ||||||
2021 |
||||||||
2022 |
||||||||
2023 |
||||||||
2024 |
||||||||
Thereafter |
||||||||
|
|
|
|
|||||
Total minimum lease payments |
$ | $ | ||||||
|
|
|||||||
Less: amount representing interest |
||||||||
|
|
|||||||
Long-term capital lease obligations as of September 30, 2020 |
$ | |||||||
|
|
Nine Months ended September 30, 2020 |
||||||||||||||||||||
Autonomy Solutions |
Other Component Sales |
Total reportable segments |
Eliminations (1) |
Total Consolidated |
||||||||||||||||
Revenue: |
||||||||||||||||||||
Revenues from external customers |
$ | $ | $ | $ | $ | |||||||||||||||
Revenues from internal customer |
( |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total Revenue |
$ | $ | $ | $ | ( |
) | $ | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Depreciation and amortization |
$ | $ | $ | $ | $ | |||||||||||||||
Operating profit (loss) |
( |
) | ( |
) | ( 56, 481 |
) | ||||||||||||||
Other significant items: |
||||||||||||||||||||
Segment assets |
( |
) | ||||||||||||||||||
Inventory |
||||||||||||||||||||
Nine Months ended September 30, 2019 |
||||||||||||||||||||
Autonomy Solutions |
Other Component Sales |
Total reportable segments |
Eliminations (1) |
Total Consolidated |
||||||||||||||||
Revenue: |
||||||||||||||||||||
Revenues from external customers |
$ | $ | $ | $ | $ | |||||||||||||||
Revenues from internal customer |
( |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total Revenue |
$ | $ | $ | $ | ( |
) | $ | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Depreciation and amortization |
$ | $ | $ | $ | $ | |||||||||||||||
Operating profit (loss) |
( |
) | ( |
) | ( |
) | ||||||||||||||
Other significant items: |
||||||||||||||||||||
Segment assets |
( |
) | ||||||||||||||||||
Inventory |
1. | Represent the eliminations of all intercompany balances and transactions during the period presented. |
As of December 31, |
||||||||
2019 |
2018 |
|||||||
Assets |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Restricted cash and cash equivalents |
||||||||
Marketable securities |
||||||||
Accounts receivable |
||||||||
Inventories |
||||||||
Other current assets |
||||||||
Total current assets |
||||||||
Restricted cash and cash equivalents |
||||||||
Property and equipment, net |
||||||||
Goodwill |
||||||||
Other long-term assets |
||||||||
Total assets |
$ | $ | ||||||
Liabilities, mezzanine equity and deficit |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued liabilities |
||||||||
Current portion of long-term debt, net |
||||||||
Bridge note payable |
||||||||
Other current liabilities |
||||||||
Total current liabilities |
||||||||
Long-term debt, net |
||||||||
Simple Agreements for Future Equity (“SAFE”) liabilities |
||||||||
Warrant liabilities |
||||||||
Other long-term liabilities |
||||||||
Total liabilities |
||||||||
Commitments and contingencies (Note 18) |
||||||||
Mezzanine equity |
||||||||
Series A preferred stock, $ |
||||||||
Deficit |
||||||||
Founders’ preferred stock, $ |
||||||||
Common stock, $ |
||||||||
Additional paid-in capital |
||||||||
Accumulated other comprehensive income (loss) |
( |
) | ||||||
Treasury stock, at cost, |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
Total deficit |
( |
) | ( |
) | ||||
Total liabilities, mezzanine equity and deficit |
$ | $ | ||||||
Year Ended December 31, |
||||||||
2019 |
2018 |
|||||||
Net sales |
$ | $ | ||||||
Cost of sales |
||||||||
Gross profit (loss) |
( |
) | ||||||
Selling and marketing expenses |
||||||||
General and administrative expenses |
||||||||
Research and development expenses |
||||||||
Operating loss |
( |
) | ( |
) | ||||
Interest income |
||||||||
Interest expense |
( |
) | ( |
) | ||||
Change in fair value of SAFE notes |
( |
) | ( |
) | ||||
Change in fair values of warrant liabilities |
( |
) | ( |
) | ||||
Loss on extinguishment of debt |
( |
) | ||||||
Other income |
||||||||
Other expense |
( |
) | ( |
) | ||||
Loss before income taxes |
( |
) | ( |
) | ||||
Income taxes |
||||||||
Net loss |
$ | ( |
) | ( |
) | |||
Net loss attributable per share to common stockholders: |
||||||||
Basic and diluted |
$ | ( |
) | $ | ( |
) | ||
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted |
||||||||
Year Ended December 31, |
||||||||
2019 |
2018 |
|||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Other comprehensive loss, net of tax: |
||||||||
Changes in unrealized gain on marketable securities |
( |
) | ||||||
Comprehensive loss |
$ | ( |
) | $ | ( |
) | ||
Series A Convertible Preferred Stock |
Founders Preferred Stock |
Common Stock |
Treasury stock |
Additional paid-in capital |
Accumulated other comprehensive loss |
Accumulated deficit |
Total deficit |
|||||||||||||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
Shares |
Amount |
Amount |
||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2017 |
$ | $ | $ | — | $ | $ | $ | $ | ( |
) | $ | ( |
) | |||||||||||||||||||||||||||||||
Issuance of restricted common stock |
||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation |
||||||||||||||||||||||||||||||||||||||||||||
Repurchase of common stock (1) |
$ | — | ||||||||||||||||||||||||||||||||||||||||||
Net loss |
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2018 |
— | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||
Conversion of SAFE into preferred stock for cash, net of issuance costs of $ |
||||||||||||||||||||||||||||||||||||||||||||
Conversion of debt into preferred stock |
||||||||||||||||||||||||||||||||||||||||||||
Issuance of Series A stock for cash, net of issuance costs of $ |
||||||||||||||||||||||||||||||||||||||||||||
Issuance of restricted common stock |
||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation |
||||||||||||||||||||||||||||||||||||||||||||
Repurchase of common stock (1) |
$ | — | ||||||||||||||||||||||||||||||||||||||||||
Conversion of SAFE into common stock |
||||||||||||||||||||||||||||||||||||||||||||
Net loss |
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||
Other comprehensive Income |
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2019 |
$ | $ | $ | $ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||||||||||||||||||||||||||||
(1) | Amounts within common stock and treasury stock round to zero. |
Year Ended December 31, |
||||||||
2019 |
2018 |
|||||||
Cash flows from operating activities: |
||||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
Depreciation and amortization |
||||||||
Change in fair value of warrants and SAFE liabilities |
||||||||
Impairment of inventories |
||||||||
Loss on disposal of property and equipment |
||||||||
Loss on extinguishment of debt |
||||||||
Share-based compensation |
||||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
( |
) | ||||||
Inventories |
( |
) | ( |
) | ||||
Other current assets |
( |
) | ||||||
Other long-term assets |
( |
) | ( |
) | ||||
Accounts payable |
( |
) | ||||||
Accrued liabilities |
( |
) | ( |
) | ||||
Other current liabilities |
||||||||
Other long-term liabilities |
( |
) | ||||||
Net cash used in operating activities |
( |
) | ( |
) | ||||
Cash flows from investing activities: |
||||||||
Purchase of marketable securities |
( |
) | ||||||
Proceeds from sale of marketable securities |
||||||||
Purchase of property and equipment |
( |
) | ( |
) | ||||
Disposal of property and equipment |
||||||||
Net cash used in investing activities |
( |
) | ( |
) | ||||
Cash flows from financing activities: |
||||||||
Settlement of SAFE notes |
( |
) | ||||||
Principal payments on financing obligations |
( |
) | ( |
) | ||||
Proceeds from the issuance of debt |
||||||||
Principal payments on capital leases |
( |
) | ( |
) | ||||
Proceeds from issuance of Series A Convertible Preferred stock |
||||||||
Proceeds from issuance of SAFE notes |
||||||||
Proceeds from issuance of restricted common stock |
||||||||
Financing costs paid |
( |
) | ||||||
Repurchase of common stock |
( |
) | ( |
) | ||||
Net cash provided by financing activities |
||||||||
Net increase (decrease) in cash and cash equivalents, and restricted cash and cash equivalents |
( |
) | ||||||
Beginning cash and cash equivalents, and restricted cash and cash equivalents |
||||||||
Ending cash and cash equivalents, and restricted cash and cash equivalents |
$ | $ | ||||||
Supplemental disclosures of cash flow information: |
||||||||
Cash paid for interest |
$ | $ | ||||||
Cash paid for income taxes |
||||||||
Supplemental disclosures of noncash investing and financing activities: |
||||||||
Conversion of Bridge Note to Series A Convertible Preferred stock |
||||||||
Conversion of SAFE notes into Common Stock |
||||||||
Conversion of SAFE notes into Series A Convertible Preferred stock |
||||||||
Assets acquired on capital leases |
||||||||
Purchases of property and equipment recorded in accounts payable and accrued liabilities |
Estimated useful lives |
||||
Computer hardware and software |
||||
Demonstration units and fleet |
||||
Machinery and equipment |
||||
Furnitures and fixtures |
||||
Vehicles |
||||
Leasehold improvements |
• | Identifying the contract, or contracts, with the customer; |
• | Identifying the performance obligations in the contract; |
• | Determining the transaction price; |
• | Allocating the transaction price to performance obligations in the contract; and |
• | Recognizing revenue when, or as, the Company satisfies performance obligations by transferring the promised good or services. |
Year Ended December 31, |
||||||||||||||||
2019 |
2018 |
|||||||||||||||
Revenue |
% of Revenue |
Revenue |
% of Revenue |
|||||||||||||
Revenue by primary geographical market: |
||||||||||||||||
North America |
$ | % | $ | % | ||||||||||||
Asia Pacific |
% | % | ||||||||||||||
Europe, Middle East, and Asia |
% | % | ||||||||||||||
Total |
% | % | ||||||||||||||
Revenue by timing of recognition: |
||||||||||||||||
Recognized at a point in time |
% | % | ||||||||||||||
Recognized over time |
% | % | ||||||||||||||
Total |
% | % | ||||||||||||||
Revenue by segment: |
||||||||||||||||
Autonomy Solutions |
% | % | ||||||||||||||
Other component sales |
% | % | ||||||||||||||
Total |
% | % | ||||||||||||||
As of December 31, |
||||
2019 |
||||
Contract liabilities, current |
$ | |||
Contract liabilities, long-term |
||||
Total |
$ | |||
Year Ended December 31, |
||||||||
2019 |
2018 |
|||||||
Beginning balance |
$ | $ | ||||||
Impact of ASC 606 adoption |
— | — | ||||||
Revenue recognized that was included in the contract liabilities beginning balance |
( |
) | ||||||
Increase due to cash received and not recognized as revenue and billings in excess of revenue recognized during the period |
— | |||||||
Customer deposits reclassified to refund liabilities |
— | — | ||||||
Ending balance |
$ | $ | ||||||
As of December 31, |
||||||||
2019 |
2018 |
|||||||
Raw materials |
$ | $ | ||||||
Work-in-process |
||||||||
Finished goods |
||||||||
Total inventory |
$ | $ | ||||||
As of December 31, |
||||||||
2019 |
2018 |
|||||||
Computer hardware and software |
$ | $ | ||||||
Demonstration fleet and demonstration units |
||||||||
Machinery and equipment |
||||||||
Furnitures and fixtures |
||||||||
Vehicles |
||||||||
Leasehold improvements |
||||||||
Capital lease assets |
||||||||
Construction in progress |
||||||||
Total property and equipment |
||||||||
Less: accumulated depreciation and amortization |
||||||||
Total property and equipment, net |
$ | $ | ||||||
As of December 31, |
||||||||
2019 |
2018 |
|||||||
Prepaid expenses |
$ | $ | ||||||
Advance payments to vendors |
— | |||||||
Prepaid rent and other |
||||||||
Other receivables |
||||||||
Total other current assets |
$ | $ | ||||||
As of December 31, |
||||||||
2019 |
2018 |
|||||||
Security deposits |
$ | $ | ||||||
Other long-term assets |
||||||||
Total other assets |
$ | $ | ||||||
As of December 31, |
||||||||
2019 |
2018 |
|||||||
Accrued expenses |
$ | $ | ||||||
Warranty liabilities |
||||||||
Contract liabilities |
||||||||
Payroll payable |
||||||||
Accrued bonuses |
||||||||
Short-term lease liabilities and other |
||||||||
Total accrued and other current liabilities |
$ | $ | ||||||
As of December 31, |
||||||||
2019 |
2018 |
|||||||
Deferred rent |
||||||||
Long-term lease liabilities |
||||||||
Total accrued and other long-term liabilities |
$ | $ | ||||||
Year Ended December 31, |
||||||||
2019 |
2018 |
|||||||
Principal amount, inclusive of accrued interest and changes in fair value, if any |
$ | |||||||
Losses reported from changes in fair value in the statement of operations |
$ | ( |
) | $ | ( |
) |
As of December 31, |
||||||||
2019 |
2018 |
|||||||
2017 Notes Principal Outstanding |
$ | $ | ||||||
Unamortized discount (2017 Notes) |
( |
) | ( |
) | ||||
2018 Notes |
||||||||
Unamortized discount (2018 Notes) |
( |
) | ( |
) | ||||
Net carrying amount |
||||||||
Less: current portion |
||||||||
Non-current portion |
$ | $ | ||||||
As of December 31, |
||||||||
2019 |
2018 |
|||||||
Notes Principal Outstanding |
$ | $ | ||||||
Unamortized discount |
( |
) | ( |
) | ||||
Net carrying amount |
||||||||
Less: current portion |
||||||||
Non-current portion |
$ | $ | ||||||
As of December 31, |
||||||||
2019 |
2018 |
|||||||
Revolving credit facility |
$ | $ | ||||||
Vehicle loan |
||||||||
Additional Equipment Loan |
||||||||
Total |
||||||||
Less: current portion |
||||||||
Non-current portion |
$ | $ | ||||||
As of December 31, 2019 |
||||
2020 |
$ | |||
2021 |
||||
2022 |
||||
2023 |
||||
2024 |
||||
Total |
||||
Less unamortized debt cost |
||||
Long-term debt |
$ | |||
As of December 31, |
||||||||
2019 |
2018 |
|||||||
2017 Warrant |
$ | $ | ||||||
2018 Warrant |
||||||||
Total |
$ | $ | ||||||
Shares Authorized |
Shares Issued and Outstanding |
Per Share Liquidation Preference |
||||||||||
Series A |
$ | |||||||||||
Series A-1 |
||||||||||||
Series A-2 |
||||||||||||
Series A-3 |
||||||||||||
Series A-4 |
||||||||||||
Series A-5 |
||||||||||||
Series A-6 |
||||||||||||
Series A-7 |
||||||||||||
Series A-8 |
||||||||||||
Series A-9 |
||||||||||||
Series A-10 |
||||||||||||
Series A-11 |
$ | |||||||||||
Effective conversion price |
||||
Series A |
$ | |||
Series A-1 |
||||
Series A-2 |
||||
Series A-3 |
||||
Series A-4 |
||||
Series A-5 |
||||
Series A-6 |
||||
Series A-7 |
||||
Series A-8 |
||||
Series A-9 |
||||
Series A-10 |
||||
Series A-11 |
Commitment Date |
Series |
Type of Consideration received (cash or settlement of other instruments) |
Effective Conversion Price |
Fair value of the Common Stock |
Number of Shares Issuable upon Conversion |
BCF |
||||||||||||||||||
6/24/2019 |
A | $ | $ | $ | — | |||||||||||||||||||
A | — | |||||||||||||||||||||||
A-1 |
||||||||||||||||||||||||
A-2 |
||||||||||||||||||||||||
A-3 |
||||||||||||||||||||||||
A-4 |
— | |||||||||||||||||||||||
A-5 |
— | |||||||||||||||||||||||
A-6 |
— | |||||||||||||||||||||||
A-7 |
— | |||||||||||||||||||||||
A-8 |
— | |||||||||||||||||||||||
A-9 |
Settlement of SAFEs | — | ||||||||||||||||||||||
A-10 |
— | |||||||||||||||||||||||
A-11 |
— | |||||||||||||||||||||||
6/26/2019 |
A | — | ||||||||||||||||||||||
7/15/2019 |
A | — | ||||||||||||||||||||||
7/22/2019 |
A | — | ||||||||||||||||||||||
$ | ||||||||||||||||||||||||
Fair Value (in thousands) Measured as of December 31, 2019 Using: |
||||||||||||||||
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||
Assets: |
||||||||||||||||
Commercial papers |
$ | — | $ | $ | — | $ | ||||||||||
Corporate debt |
— | — | ||||||||||||||
Treasury bills |
— | — | ||||||||||||||
Total fair value |
— | |||||||||||||||
Liabilities: |
||||||||||||||||
SAFEs |
— | — | — | — | ||||||||||||
2017 Warrants |
— | — | ||||||||||||||
2018 Warrants |
— | — | ||||||||||||||
Total fair value |
$ | — | $ | — | $ | $ | ||||||||||
Fair Value (in thousands) Measured as of December 31, 2018 Using: |
||||||||||||||||
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||
Liabilities: |
||||||||||||||||
SAFEs |
$ | — | $ | — | $ | $ | ||||||||||
2017 Warrants |
— | — | ||||||||||||||
2018 Warrants |
— | — | ||||||||||||||
Total fair value |
$ | — | $ | — | $ | $ | ||||||||||
For the year ended December 31, 2019 |
||||||||||||
SAFEs |
2017 Warrants |
2018 Warrants |
||||||||||
Balance-beginning of year |
$ | $ | $ | |||||||||
Additions |
— | |||||||||||
Exercise or conversion |
( |
) | ||||||||||
Measurement adjustments |
||||||||||||
Balance-end of year |
$ | $ | $ | |||||||||
For the year ended December 31, 2018 |
||||||||||||
SAFEs |
2017 Warrants |
2018 Warrants |
||||||||||
Balance-beginning of year |
$ | $ | $ | |||||||||
Additions |
||||||||||||
Exercise or conversion |
||||||||||||
Measurement adjustments |
||||||||||||
Balance-end of year |
$ | $ | $ | |||||||||
As of December 31, |
||||||||
2019 |
2018 |
|||||||
Numerator: |
||||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Deemed dividend attributable to BCF accretion |
( |
) | — | |||||
Net loss attributable to common shareholders |
( |
) | ( |
) | ||||
Denominator: |
||||||||
Weighted average Common shares outstanding- Basic |
||||||||
Dilutive effect of potential common shares |
— | — | ||||||
Weighted average Common shares outstanding- Diluted |
||||||||
Net loss per shares attributable to Common shareholders- Basic and Diluted |
$ | ( |
) | $ | ( |
) | ||
As of December 31, |
||||||||
2019 |
2018 |
|||||||
Warrants |
||||||||
Stock Options |
||||||||
Restricted Stock |
||||||||
Series A Convertible Preferred Stock |
||||||||
Founders Preferred Stock |
||||||||
SAFE |
||||||||
Total |
||||||||
2019 |
||||
Expected term (years) (1) |
||||
Current stock value |
$ | |||
Expected volatility (2) |
||||
Risk-free interest rate (3) |
||||
Dividend yield (4) |
(1) | The expected term is the length of time the grant is expected to be outstanding before it is exercised or terminated. This number is calculated as the midpoint between the vesting term and the original contractual term (contractual period to exercise). If the option contains graded vesting, then the vesting term would be based on the vesting pattern. |
(2) | Volatility, or the standard deviation of annualized returns, was calculated based on comparable companies’ reported volatilities. |
(3) | Risk free rate was obtained from US treasury notes for the expected terms noted as of the valuation date. |
(4) | The Company has assumed a dividend yield of zero as it has no plans to declare dividends in the foreseeable future. |
Number of Common Stock Options |
Weighted- Average Exercise Price |
Weighted- Average Remaining Contractual Life (Years) |
Aggregate Intrinsic Value (In Thousands) |
|||||||||||||
Outstanding as of January 1, 2019 |
— | $ | — | — | $ | — | ||||||||||
Granted |
||||||||||||||||
Exercised |
— | — | — | |||||||||||||
Forfeited |
( |
) | ||||||||||||||
Expired |
— | — | — | |||||||||||||
Outstanding as of December 31, 2019 |
||||||||||||||||
Vested and exercisable as of December 31, 2019 |
||||||||||||||||
Vested and expected to vest as of December 31, 2019 |
$ | $ | ||||||||||||||
Shares |
Weighted Average Grant Date Fair Value per Share |
|||||||
Outstanding as of December 31, 2017 |
$ | |||||||
Granted |
||||||||
Forfeited |
( |
) | ||||||
Vested |
( |
) | ||||||
Outstanding as of December 31, 2018 |
||||||||
Granted |
||||||||
Forfeited |
( |
) | ||||||
Vested |
( |
) | ||||||
Outstanding as of December 31, 2019 |
$ | |||||||
Shares |
Weighted Average Grant Date Fair Value per Share |
|||||||
Outstanding as of December 31, 2017 |
$ | |||||||
Granted |
||||||||
Forfeited |
( |
) | ||||||
Vested |
( |
) | ||||||
Outstanding as of December 31, 2018 |
||||||||
Granted |
— | — | ||||||
Forfeited |
— | — | ||||||
Vested |
( |
) | ||||||
Outstanding as of December 31, 2019 |
$ | |||||||
Year Ended December 31, |
||||||||
2019 |
2018 |
|||||||
Cost of sales |
$ | $ | ||||||
Research and development |
||||||||
Sales and marketing |
||||||||
General and administrative |
||||||||
Total |
$ | $ | ||||||
Year Ended December 31, |
||||||||
2019 |
2018 |
|||||||
Domestic |
$ | $ | ||||||
Foreign |
||||||||
Loss before income taxes |
$ | $ | ||||||
Year Ended December 31, |
||||||||
2019 |
2018 |
|||||||
U.S. federal provision at statutory rate |
% | % | ||||||
State income taxes, net of federal benefit |
||||||||
Tax credits |
||||||||
Permanent items |
( |
) | ( |
) | ||||
Uncertain tax benefits |
( |
) | ( |
) | ||||
Change in valuation allowance |
( |
) | ( |
) | ||||
Effective tax rate |
% | % | ||||||
Year Ended December 31, |
||||||||
2019 |
2018 |
|||||||
Deferred tax assets: |
||||||||
Net operating loss carry forward |
$ | $ | ||||||
Tax credits |
||||||||
Accruals and reserves |
||||||||
Stock-based compensation |
||||||||
Other |
||||||||
Total deferred tax assets |
||||||||
Valuation allowance |
( |
) | ( |
) | ||||
Total deferred tax asset |
||||||||
Deferred tax liabilities: |
||||||||
Depreciation and amortization |
||||||||
Total deferred tax liabilities |
||||||||
Net deferred tax assets (liabilities) |
$ | $ | ||||||
Year Ended December 31, |
||||||||
2019 |
2018 |
|||||||
Unrecognized tax benefits as of the beginning of the year |
$ | $ | ||||||
Increases related to prior year tax provisions |
||||||||
Decrease related to prior year tax provisions |
||||||||
Increase related to current year tax provisions |
||||||||
Statue lapse |
||||||||
Unrecognized tax benefits as of the end of the year |
$ | $ | ||||||
Capital Leases |
Operating Leases |
|||||||
2020 |
$ | $ | ||||||
2021 |
||||||||
2022 |
||||||||
2023 |
||||||||
2024 |
||||||||
Thereafter |
||||||||
Total minimum lease payments |
$ | |||||||
Less: amount representing interest |
||||||||
Long-term capital lease obligations as of December 31, 2019 |
$ | |||||||
Year ended December 31, 2019 |
||||||||||||||||||||
Autonomy Solutions |
Other Component Sales |
Total reportable segments |
Eliminations (1) |
Total Consolidated |
||||||||||||||||
Revenue: |
||||||||||||||||||||
Revenues from external customers |
$ | $ | $ | $ | $ | |||||||||||||||
Revenues from internal customer |
( |
) | ||||||||||||||||||
Total Revenue |
( |
) | ||||||||||||||||||
Depreciation and amortization |
||||||||||||||||||||
Operating loss |
( |
) | ( |
) | ( |
) | ||||||||||||||
Other significant items: |
||||||||||||||||||||
Segment assets |
( |
) | ||||||||||||||||||
Inventory |
$ | $ | $ | $ | $ |
Year ended December 31, 2018 |
||||||||||||||||||||
Autonomy Solutions |
Other Component Sales |
Total reportable segments |
Eliminations (1) | Total Consolidated |
||||||||||||||||
Revenue: |
||||||||||||||||||||
Revenues from external customers |
$ | $ | $ | $ | $ | |||||||||||||||
Revenues from internal customer |
( |
) | ||||||||||||||||||
Total Revenue |
( |
) | ||||||||||||||||||
Depreciation and amortization |
||||||||||||||||||||
Operating loss |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Other significant items: |
||||||||||||||||||||
Segment assets |
( |
) | ||||||||||||||||||
Inventory |
$ | $ | $ | $ | $ |
1. | Represent the eliminations of all intercompany balances and transactions during the period presented. |
September 30, 2020 (unaudited) |
December 31, 2019 (audited) |
|||||||
CURRENT ASSETS: |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Prepaid assets |
||||||||
Total current assets |
||||||||
Deferred income tax |
— | |||||||
Investments and cash held in Trust Account |
||||||||
Total assets |
$ | $ | ||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
Current liabilities: |
||||||||
Accrued expenses, formation and offering costs |
$ | $ | ||||||
State franchise tax accrual |
||||||||
Current income tax and interest payable |
||||||||
Total current liabilities |
||||||||
Deferred underwriting compensation |
||||||||
Total liabilities |
$ | $ | ||||||
Commitments and Contingencies: |
||||||||
Class A Common Stock subject to possible redemption, |
||||||||
Stockholders’ equity: |
||||||||
Preferred stock, $ |
||||||||
Common stock |
||||||||
Class A Common Stock, $ |
||||||||
Class F Common Stock, $ |
||||||||
Additional paid-in capital |
||||||||
Retained earnings |
||||||||
Total stockholders’ equity |
||||||||
Total liabilities and stockholders’ equity |
$ | $ | ||||||
Three Months Ended September 30, 2020 |
Three Months Ended September 30, 2019 |
Nine Months Ended September 30, 2020 |
Nine Months Ended September 30, 2019 |
|||||||||||||
Revenues |
$ | — | $ | — | $ | — | $ | — | ||||||||
Professional fees and other expenses |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
State franchise taxes, other than income tax |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Net loss from operations |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Other income—interest income |
||||||||||||||||
Net income/(loss) before income taxes |
$ | ( |
) | $ | $ | ( |
) | $ | ||||||||
Income tax provision and interest |
( |
) | ( |
) | ( |
) | ||||||||||
Net income/(loss) attributable to common shares |
$ | ( |
) | $ | $ | ( |
) | $ | ||||||||
Net income/(loss) per ordinary share: |
||||||||||||||||
Class A ordinary shares—basic and diluted |
$ | ( |
) | $ | $ | ( |
) | $ | ||||||||
Class F ordinary shares—basic and diluted |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
Three Months Ended September 30, 2019 |
||||||||||||||||||||||||||||
Class A Common Stock |
Class F Common Stock |
Additional Paid-In Capital |
Retained Earnings |
Stockholders’ Equity |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
Beginning Balance at July 1, 2019 |
$ | $ | $ | $ | $ | |||||||||||||||||||||||
Class A common stock subject to possible redemption; |
( |
) | ( |
) | — | — | ( |
) | — | ( |
) | |||||||||||||||||
Net income |
— | — | — | — | — | |||||||||||||||||||||||
Balance at September 30, 2019 |
$ | $ | $ | $ | $ | |||||||||||||||||||||||
Nine Months Ended September 30, 2019 |
||||||||||||||||||||||||||||
Class A Common Stock |
Class F Common Stock |
Additional Paid-In Capital |
Retained Earnings/ (Acc. Deficit) |
Stockholders’ Equity |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
Beginning Balance at January 1, 2019 |
— | $ | — | $ | $ | $ | ( |
) | $ | |||||||||||||||||||
Forfeited Class F Common stock by Sponsor |
— | — | ( |
) | ( |
) | — | — | ||||||||||||||||||||
Proceeds from initial public offering of Units on February 5, 2019 at $ |
— | — | — | |||||||||||||||||||||||||
Sale of |
— | — | — | — | — | |||||||||||||||||||||||
Underwriters discounts |
— | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||
Offering costs charged to additional paid-in capital |
— | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||
Deferred underwriting compensation |
— | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||
Class A common stock subject to possible redemption; |
( |
) | ( |
) | — | — | ( |
) | — | ( |
) | |||||||||||||||||
Net income |
— | — | — | — | — | |||||||||||||||||||||||
Balance at September 30, 2019 |
$ | $ | $ | $ | $ | |||||||||||||||||||||||
Three Months Ended September 30, 2020 |
||||||||||||||||||||||||||||
Class A Common Stock |
Class F Common Stock |
Additional Paid-In Capital |
Retained Earnings |
Stockholders’ Equity |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
Beginning Balance at July 1, 2020 |
$ | $ | $ | $ | $ | |||||||||||||||||||||||
Class A common stock subject to possible redemption; |
— | — | — | |||||||||||||||||||||||||
Net loss |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
Balance at September 30, 2020 |
$ | $ | $ | $ | $ | |||||||||||||||||||||||
Nine Months Ended September 30, 2020 |
||||||||||||||||||||||||||||
Class A Common Stock |
Class F Common Stock |
Additional Paid-In Capital |
Retained Earnings |
Stockholders’ Equity |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
Beginning Balance at January 1, 2020 |
$ | $ | $ | $ | $ | |||||||||||||||||||||||
Class A common stock subject to possible redemption; |
— | — | — | |||||||||||||||||||||||||
Net loss |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
Balance at September 30, 2020 |
$ | $ | $ | $ | $ | |||||||||||||||||||||||
Nine Months Ended September 30, 2020 |
Nine Months Ended September 30, 2019 |
|||||||
Cash flows from operating activities: |
||||||||
Net income/(loss) |
$ | ( |
) | $ | ||||
Changes in state franchise tax accrual |
( |
) | ||||||
Changes in prepaid assets and deferred costs |
( |
) | ||||||
Changes in deferred offering costs |
— | |||||||
Changes in accrued expenses, formation and offering costs |
( |
) | ||||||
Changes in current income tax and interest payable |
( |
) | ||||||
Changes in deferred income tax |
||||||||
Net cash provided by/(used in) operating activities |
( |
) | ||||||
Cash flows from investing activities: |
||||||||
Cash deposited in Trust Account |
— | ( |
) | |||||
Interest reinvested in Trust Account |
( |
) | ||||||
Net cash provided by/(used in) investing activities |
( |
) | ||||||
Cash flows from financing activities: |
||||||||
Proceeds from sale of Units in initial public offering |
— | |||||||
Proceeds from sale of Private Placement Warrants to Sponsor |
— | |||||||
Repayment of notes and advances payable—related party |
— | ( |
) | |||||
Payment of underwriters’ discounts and commissions |
— | ( |
) | |||||
Payment of accrued offering costs |
— | ( |
) | |||||
Net cash provided by financing activities |
— | |||||||
Increase/(decrease) in cash |
( |
) | ||||||
Cash at beginning of period |
||||||||
Cash at end of period |
$ | $ | ||||||
Supplemental disclosure of cash and non-cash financing activities: |
||||||||
Deferred underwriting compensation |
$ | — | $ | |||||
Cash paid for income and state franchise taxes |
1. |
Organization and Business Operations |
2. |
Significant Accounting Policies |
For the Three Months Ended September 30, 2020 |
For the Three Months Ended September 30, 2019 |
For the Nine Months Ended September 30, 2020 |
For the Nine Months Ended September 30, 2019 |
|||||||||||||||||||||||||||||
Class A |
Class F |
Class A |
Class F |
Class A |
Class F |
Class A |
Class F |
|||||||||||||||||||||||||
Basic and diluted net income/(loss) per share: |
||||||||||||||||||||||||||||||||
Numerator: |
||||||||||||||||||||||||||||||||
Allocation of net income/(loss) |
$ | ( |
) | $ | ( |
) | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | $ | ( |
) | ||||||||||||
Denominator: |
||||||||||||||||||||||||||||||||
Weighted-average shares outstanding |
||||||||||||||||||||||||||||||||
Basic and diluted net income/(loss) per share |
$ | ( |
) | $ | ( |
) | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | $ | ( |
) |
3. |
Public Offering |
4. |
Related Party Transactions |
5. |
Deferred Underwriting Compensation |
6. |
Income Taxes |
7. |
Investments and cash held in Trust |
8. |
Fair Value Measurement |
Description |
September 30, 2020 |
Quoted Prices in Active Markets (Level 1) |
Significant Other Observable Inputs (Level 2) |
Significant Other Unobservable Inputs (Level 3) |
||||||||||||
Investments and cash held in Trust Account |
— | — | ||||||||||||||
Total |
$ | $ | $ | — | $ | — | ||||||||||
9. |
Stockholders’ Equity |
10. |
Risk and Contingencies |
11. |
Subsequent Events |
December 31, 2019 |
December 31, 2018 |
|||||||
CURRENT ASSETS: |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Deferred offering costs |
— | |||||||
Prepaid assets |
— | |||||||
Total current assets |
||||||||
Deferred income tax |
— | |||||||
Investments and cash held in Trust Account |
— | |||||||
Total assets |
$ | $ | ||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
Current liabilities: |
||||||||
Accrued expenses, formation and offering costs |
$ | $ | ||||||
State franchise tax accrual |
||||||||
Notes and advances payable—related party |
— | |||||||
Income tax payable |
— | |||||||
Total current liabilities |
||||||||
Deferred underwriting compensation |
— | |||||||
Total liabilities |
$ | $ | ||||||
Commitments and Contingencies: |
||||||||
Class A subject to possible redemption, - |
— | |||||||
Stockholders’ equity: |
||||||||
Preferred stock, $ |
||||||||
Common stock |
||||||||
Class A common stock, $ - - |
— | |||||||
Class F common stock, $ |
||||||||
Additional paid-in-capital |
||||||||
Retained earnings/(accumulated deficit) |
( |
) | ||||||
Total stockholders’ equity |
||||||||
Total liabilities and stockholders’ equity |
$ | $ | ||||||
Year ended December 31, 2019 |
For the Period from August 28, 2018 (inception) to December 31, 2018 |
|||||||
Professional fees and other expenses |
( |
) | ( |
) | ||||
State franchise taxes, other than income tax |
( |
) | ( |
) | ||||
Loss from operations |
( |
) | ( |
) | ||||
Other income—interest income |
— | |||||||
Net income/(loss) before income taxes |
$ | $ | ( |
) | ||||
Provision for income tax |
( |
) | — | |||||
Net income/(loss) attributable to common shares |
$ | $ | ( |
) | ||||
Net income/(loss) per ordinary share: |
||||||||
Class A ordinary shares—basic and diluted |
$ | $ | — | |||||
Class F ordinary shares—basic and diluted |
$ | ( |
) | $ | ( |
) | ||
Class A Ordinary Shares |
Class F Ordinary Shares |
Additional Paid-In Capital |
Accumulated Deficit |
Stockholders’ Equity |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
Balance at August 28, 2018 (inception) |
$ | $ | $ | $ | $ | |||||||||||||||||||||||
Sale of Class F common stock to sponsor in October 2018 |
— | — | $ | $ | $ | — | $ | |||||||||||||||||||||
Net loss |
— | — | — | $ | — | $ | — | $ | ( |
) | $ | ( |
) | |||||||||||||||
Balance at December 31, 2018 |
— | $ | — | $ | $ | $ | ( |
) | $ | |||||||||||||||||||
For the Year ended December 31, 2019 |
||||||||||||||||||||||||||||
Class A Ordinary Shares |
Class F Ordinary Shares |
Additional Paid-In Capital |
Retained Earnings |
Stockholders’ Equity |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
Forfeited Class F Common stock by Sponsor |
— | — | ( |
) | ( |
) | — | — | ||||||||||||||||||||
Proceeds from initial public offering of Units on February 5, 2019 at $ |
— | — | — | |||||||||||||||||||||||||
Sale of |
— | — | — | — | — | |||||||||||||||||||||||
Underwriters discounts |
— | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||
Offering costs charged to additional paid-in capital |
— | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||
Deferred underwriting compensation |
— | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||
Class A common stock subject to possible redemption; |
( |
) | ( |
) | — | — | ( |
) | — | ( |
) | |||||||||||||||||
Net income |
— | — | — | — | — | |||||||||||||||||||||||
Balance at December 31, 2019 |
$ | $ | $ | $ | $ | |||||||||||||||||||||||
Year Ended December 31, 2019 |
For the Period from August 28, 2018 (inception) to December 31, 2018 |
|||||||
Cash flows from operating activities: |
||||||||
Net income/(loss) |
$ | $ | ( |
) | ||||
Changes in state franchise tax accrual |
||||||||
Changes in prepaid assets |
( |
) | — | |||||
Changes in deferred offering costs |
( |
) | ||||||
Changes in current income tax |
||||||||
Changes in deferred income tax |
( |
) | — | |||||
Changes in accrued expenses, formation and offering costs |
( |
) | ||||||
Net cash provided by/(used in) operating activities |
( |
) | ||||||
Cash flows from investing activities: |
||||||||
Cash deposited in Trust Account |
( |
) | — | |||||
Interest reinvested in Trust Account |
( |
) | — | |||||
Net cash used in investing activities |
( |
) | — | |||||
Cash flows from financing activities: |
||||||||
Proceeds from notes and advances payable—related party |
— | |||||||
Proceeds from sale of Class F common stock to Sponsor |
— | |||||||
Proceeds from sale of Units in initial public offering |
— | |||||||
Proceeds from sale of Private Placement Warrants to Sponsor |
— | |||||||
Repayment of notes and advances payable—related party |
( |
) | — | |||||
Payment of underwriter’s discounts and commissions |
( |
) | — | |||||
Payment of accrued offering costs |
( |
) | — | |||||
Net cash provided by financing activities |
||||||||
Increase in cash |
||||||||
Cash at beginning of period |
— | |||||||
Cash at end of period |
$ | $ | ||||||
Supplemental disclosure of non-cash financing activities: |
||||||||
Deferred underwriting compensation |
$ | $ | — | |||||
Cash paid for income and state franchise taxes |
$ | $ | — |
Year Ended December 31, 2019 |
For the Period from August 28, 2018 (inception) to December 31, 2018 |
|||||||||||||||
Class A |
Class F |
Class A |
Class F |
|||||||||||||
Basic and diluted net income/(loss) per share: |
||||||||||||||||
Numerator: |
||||||||||||||||
Allocation of net income/(loss) |
$ | $ | ( |
) | $ | — | $ | ( |
) | |||||||
Denominator: |
||||||||||||||||
Weighted-average shares outstanding |
— | |||||||||||||||
Basic and diluted net income/(loss) per share |
$ | $ | ( |
) | $ | — | $ | ( |
) |
Year Ended December 31, 2019 |
Year Ended December 31, 2018 |
|||||||
Income tax expense at the federal statutory rate |
$ | $ | ( |
) | ||||
State income taxes—net of federal income tax benefits |
( |
) | ( |
) | ||||
Change in valuation allowance |
||||||||
|
|
|
|
|||||
Total income tax expense (benefit) |
$ | $ | — | |||||
|
|
|
|
Year Ended December 31, 2019 |
Year Ended December 31, 2018 |
|||||||
Current income tax expense |
||||||||
Federal |
$ | $ | — | |||||
State |
— | — | ||||||
|
|
|
|
|||||
Total current income tax expense |
$ | $ | — | |||||
|
|
|
|
|||||
Deferred income tax expense |
||||||||
Federal |
$ | ( |
) | $ | — | |||
State |
— | — | ||||||
|
|
|
|
|||||
Total deferred income tax expense |
$ | ( |
) | $ | — | |||
|
|
|
|
|||||
Provision for income taxes |
$ | $ | — | |||||
|
|
|
|
Year Ended December 31, 2019 |
Year Ended December 31, 2018 |
|||||||
Deferred tax assets/(liabilities) |
||||||||
Tax attribute carryovers |
$ | $ | ||||||
Valuation allowance |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Net deferred tax assets/(liabilities) |
$ | $ | ||||||
|
|
|
|
Description |
December 31, 2019 |
Quoted Prices in Active Markets (Level 1) |
Significant Other Observable Inputs (Level 2) |
Significant Other Unobservable Inputs (Level 3) |
||||||||||||
Investments and cash held in Trust Account |
— | — | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total |
$ | $ | $ | — | $ | — | ||||||||||
|
|
|
|
|
|
|
|
Amount |
||||
SEC registration fee |
$ | 565,535.30 | ||
Legal fees and expenses |
* | |||
Accounting fees and expenses |
* | |||
Miscellaneous |
* | |||
|
|
|||
Total |
$ | * | ||
|
|
* | These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be defined at this time. |
* | Schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The registrant hereby agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request. |
† | Indicates a management contract or compensatory plan, contract or arrangement. |
(a) | The undersigned registrant hereby undertakes: |
(1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
(i) | To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; |
(ii) | To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and |
(iii) | To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; |
(2) | That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
(3) | To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
(4) | That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. |
(5) | That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: |
(i) | Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
(ii) | Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
(iii) | The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and |
(iv) | Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
(b) | Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue. |
LUMINAR TECHNOLOGIES, INC. | ||
By: | /s/ Austin Russell | |
Austin Russell | ||
President, Chief Executive Officer and Chairman of the Board of Directors |
Signature |
Title |
Date | ||
/s/ Austin Russell Austin Russell |
President, Chief Executive Officer and Chairman of the Board of Directors ( Principal Executive Officer |
December 23, 2020 | ||
/s/ Thomas J. Fennimore Thomas J. Fennimore |
Chief Financial Officer ( Principal Financial and Accounting Officer |
December 23, 2020 | ||
/s/ Alec E. Gores Alec E. Gores |
Director |
December 23, 2020 | ||
/s/ Benjamin J. Kortlang Benjamin J. Kortlang |
Director |
December 23, 2020 | ||
/s/ Scott A. McGregor Scott A. McGregor |
Director |
December 23, 2020 | ||
/s/ Matthew J. Simoncini Matthew J. Simoncini |
Director |
December 23, 2020 |